Genetically modified bacteria with stable mutations that do not require antibiotic markers, and their generation systems and methods.
By introducing chromosome-disrupting auxotrophic genes and phosphate-regulating genes into virulent pathogens, stable mutant attenuated bacteria are generated, solving the safety and stability issues in existing technologies and achieving antibiotic-free gene modification, which is suitable for the delivery of live vaccines and therapeutic payloads.
Patent Information
- Application Number
- CN202580021901.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-01-18
- Filing Date
- 2025-01-17
- Publication Date
- 2026-11-17
AI Technical Summary
Existing attenuated bacteria face safety, stability, and risk of regaining virulence issues in cancer therapy and vaccine development, making it difficult to achieve targeted colonization and elicit an appropriate immune response.
By introducing chromosome-disrupting auxotrophic genes and genes involved in phosphate regulation into virulent pathogens, and by introducing DNA rescue molecules with functional copies, genetically modified bacteria can be generated, reducing the risk of regaining virulence.
This technology enables the generation of stable mutant attenuated bacteria without antibiotic biomarkers, improving safety and reliability, reducing the potential for reversal to virulent strains, and is suitable for the delivery of live vaccines and therapeutic payloads.
Smart Images

Figure CN123125319A_ABST
Abstract
Description
[0001] Citations of relevant applications This application claims the benefit of U.S. Provisional Patent Application Serial No. 63 / 622,157, filed January 18, 2024. The contents of the foregoing document are incorporated herein by reference in their entirety. Technical Field
[0002] This application generally relates to the field of genetically modified bacteria with stable mutations that do not require antibiotic markers, and the systems and methods for their generation.
[0003] sequence list This specification is submitted along with the electronic sequence list. The sequence list file is named PhoenixSeqListing.xml, was generated on January 9, 2025, and is 83 kb in size. The information in the electronic format of the sequence list is incorporated herein by reference in its entirety.
[0004] copyright This patent document contains a portion of copyrighted material. The copyright holder does not object to any reproduction of the patent document or patent disclosure as shown in the Patent and Trademark Office's patent documents or records, but otherwise reserves all copyright rights. Background Technology
[0005] Over the past few decades, the use of live attenuated bacteria in medical applications has attracted significant interest, particularly in vaccine development and cancer therapies. Attenuated bacteria are strains modified to reduce their virulence while retaining their ability to interact with the host's immune system, ensuring safety. Leveraging their natural ability to infect and proliferate within host tissues, these bacteria serve as highly efficient platforms for delivering antigens or therapeutic molecules.
[0006] In the field of vaccine development, attenuated bacteria have been widely used as vectors for expressing heterologous antigens. Their ability to induce (systemic and mucosal) immune responses makes them a versatile alternative to traditional vaccine platforms.
[0007] Beyond vaccines, attenuated bacteria are emerging as promising therapeutic delivery systems for treating various pathologies, such as cancer. For example, bacterial replication in tumors can activate the immune system to recognize tumor cells as foreign invaders and initiate cytotoxic T cells to kill the cancer. Taking advantage of the hypoxic and immunosuppressive conditions common in solid tumors, certain bacterial strains naturally home to and proliferate within the tumor microenvironment. Genetic engineering further expands their potential, enabling them to deliver therapeutic agents, such as cytokines, cytotoxic proteins, or immune checkpoint inhibitors, directly to the tumor site. This targeted approach not only enhances therapeutic efficacy but also minimizes systemic toxicity.
[0008] Despite these advances, the practical application of attenuated bacteria in cancer therapy and as vaccine vectors still faces several challenges. These include ensuring the safety and stability of attenuated bacterial strains, achieving consistent colonization or delivery to target sites, and evoking appropriate immune responses. Furthermore, further innovation is needed to enhance the specificity, payload capacity, and immunogenicity of these bacterial systems, as well as to reduce the potential for attenuated live vaccine strains to revert to virulent strains.
[0009] In light of the above, there is a need to provide attenuated bacteria with stable mutations and a reduced risk of regaining virulence, thereby enhancing their safety and reliability in medical applications. Summary of the Invention
[0010] This invention presents a series of concepts in a simplified form, which will be further described in the detailed embodiments below. This invention is not intended to identify any critical or essential aspects of the claimed subject matter.
[0011] In a broad, non-limiting aspect, this disclosure relates to a composition comprising genetically modified bacteria, wherein the genetically modified bacteria comprise: chromosomal disruption in auxotrophic genes and in one or more genes involved in phosphate regulation, and a DNA rescue molecule comprising a functional copy of the auxotrophic genes, wherein the genetically modified bacteria are derived from a virulent pathogen containing a virulence plasmid.
[0012] In a broad, non-limiting aspect, this disclosure relates to a method for inducing an immune response in a host, the method comprising administering to the host an effective amount of the composition described herein.
[0013] In a broad, non-limiting aspect, this disclosure relates to a method for preparing a live attenuated vaccine from a virulent pathogen containing a virulence plasmid, comprising inducing chromosomal damage in the virulent pathogen, the chromosomal damage being in auxotrophic genes and in one or more genes involved in phosphate regulation, and introducing a DNA rescue molecule containing a functional copy of the auxotrophic gene into the bacteria.
[0014] In a broad, non-limiting aspect, this disclosure relates to a vaccine for the prevention of bacterial infectious diseases comprising the composition described herein and pharmaceutically or veterinarily acceptable excipients, diluents, or carriers.
[0015] In a broad, non-limiting aspect, this disclosure relates to a method for delivering a therapeutic payload in cancer treatment, comprising administering the composition described herein to a host suffering from cancer, wherein the DNA rescue molecule further comprises a recombinant gene encoding the therapeutic payload.
[0016] All features of the exemplary embodiments described in this disclosure, which are not mutually exclusive, can be combined with each other. Elements of one embodiment may be used in other embodiments without further mention. Other aspects and features of the invention will become clear to those skilled in the art after reviewing the following detailed description in conjunction with the accompanying drawings. Attached Figure Description
[0017] This patent or application document contains at least one color drawing. Upon request and payment of the necessary fees, the Patent Office will provide a copy of this patent or application publication with the color drawing.
[0018] The following detailed description of specific exemplary embodiments is provided with reference to the accompanying drawings, in which: Figure 1A These are non-limiting illustrations based on some embodiments of the present disclosure, depicting Escherichia coli... pst Operators and glmS The relative chromosomal location of genes (above) and their disruption (through deletion). pst and glmS Gene strategy (see diagram below).
[0019] Figure 1B The non-limiting illustrations based on some embodiments of this disclosure depict a system comprising a destroyed chromosome. pst Operators and glmS Genes, and their respective functions glmS Gene plasmid vectors and cassettes.
[0020] Figure 2 The plasmid map of pIJ355 is depicted in non-limiting color illustrations according to some embodiments of the present disclosure.
[0021] Figure 3 A to Figure 3 D is a non-limiting color image of recombinant *E. coli* grown on various Luria-Bertani (LB) agar plates. According to some embodiments of this disclosure, the recombinant *E. coli* includes disrupted chromosomes. pst Operators and glmS Gene. Figure 3 A: LB agar plate. Figure 3 B: LB agar plates supplemented with N-acetylglucosamine (NAG) (250 μg / ml). Figure 3 C: LB agar plates supplemented with disodium 5-bromo-4-chloro-3-indolyl phosphate (BCIP) (50 μg / ml). Figure 3D: LB agar plates supplemented with BCIP (50 μg / ml) and NAG (250 μg / ml). This growth plot shows that... pst Operators and glmS Chromosomal damage to the gene makes the bacteria auxotrophic to NAG and can be identified as blue colonies in culture media supplemented with chromogenic substrate.
[0022] Figure 4 The plasmid map of pIJ346 is depicted in non-limiting color illustrations according to some embodiments of the present disclosure.
[0023] Figure 5 The plasmid map of pIJ379 is depicted in non-limiting color illustrations according to some embodiments of the present disclosure.
[0024] Figure 6 A to Figure 6 D is a non-limiting color image of genetically modified *E. coli* grown on various LB agar plates. According to some embodiments of this disclosure, the genetically modified *E. coli* are obtained from… Figure 3 A- Figure 3 D's E. coli, which has been transformed to contain auxotrophic rescue genes on the recombinant pAPEC-1 plasmid. glmS Gene. Figure 6 A: Add LB agar plates containing BCIP (50 μg / ml). Figure 6 B: LB agar plates supplemented with NAG (250 μg / ml). Figure 6 C: LB agar plates supplemented with BCIP (50 μg / ml). Figure 6 D: LB agar plates supplemented with BCIP (50 μg / ml) and NAG (250 μg / ml). This growth plot demonstrates the rescue of plasmids. glmS Genes compensated glmS Chromosomal damage to genes.
[0025] Figure 7A Based on non-limiting images of PCR products from some embodiments of this disclosure, the presence of genetically modified *E. coli* bacteria in the samples was confirmed. glmS-pstSCA Gene disruption. The ladder used was Thermoscientific™ GeneRuler 1 kb Plus DNA Ladder, catalog number: SM1331.
[0026] Figure 7B This is based on some embodiments of the present disclosure. Figure 7AA non-restricted illustration of a genetically modified *E. coli* bacterium. This bacterium is shown to still express the O antigen, fimbriae, LPS, etc., which are common antigens recognized by the immune system in response to infection.
[0027] Figures 8A to 8C According to some embodiments of this disclosure, at 6, 24, and 48 hours after challenge with toxic O7 APEC, genetically modified O7 APEC ( ΔglmS-pstSCA- pAPEC-1 ΔiucABCD ΔiroBCDE::glmS Unrestricted graphical representation of bacterial counts in the blood of vaccinated and unvaccinated chickens. Results are reported as colony-forming units (CFU) per milliliter of blood. Dots represent individual values of CFU per chicken's blood. The black line represents the median level of colonization. Statistical significance is stated based on a p-value ≤ 0.05. Pairwise statistical differences between vaccinated and unvaccinated groups were assessed using the nonparametric Mann-Whitney test.
[0028] Figures 9A to 9C According to some embodiments of this disclosure, 48 hours after challenge with toxic O7 APEC, genetically modified O7 APEC ( ΔglmS-pstSCA- pAPEC-1 ΔiucABCD ΔiroBCDE::glmS Unrestricted graphical representation of bacterial counts in organs (lungs, spleen, and liver) of vaccinated and unvaccinated chickens. Results are reported as CFU per gram of tissue. Dots represent individual values of CFU per organ per chicken. The black line = median level of colonization. Statistical significance is stated based on a p ≤ 0.05 level. Statistical differences between pairwise comparisons between vaccinated and unvaccinated groups were assessed using the nonparametric Mann-Whitney test.
[0029] Figure 10 According to some embodiments of this disclosure, 48 hours after challenge with toxic O7 APEC, genetically modified O7 APEC ( ΔglmS-pstSCA- pAPEC-1 ΔiucABCD ΔiroBCDE::glmS Unrestricted color scatter plots representing inflammatory lesions in the air sacs of vaccinated and unvaccinated chickens. Vaccination was administered via intragastric administration. Each dot represents the lesion score of an individual bird. Bars represent the mean of the lesion scores for a group of birds in each group. Statistical significance is stated based on a p-value ≤ 0.05. Pairwise statistical differences between vaccinated and unvaccinated groups were assessed using the nonparametric Mann-Whitney test.
[0030] Figure 11 Based on some embodiments of this disclosure, the values of genetically modified O7 APEC were calculated at 24 and 48 hours after challenge with toxic O7 APEC. ΔglmS-pstSCA-pAPEC-1 ΔiucABCD ΔiroBCDE::glmS The percentage difference in weight between vaccinated and unvaccinated chickens is represented graphically in an unrestricted color. Dots represent individual values of chicken weight. Bars represent the mean weight change of surviving birds in each group. The vertical line above the bars represents the standard deviation. Statistical significance is stated based on a p-value ≤ 0.05. The statistical difference between pairwise comparisons between vaccinated and unvaccinated groups was assessed using the nonparametric Mann-Whitney test.
[0031] Figure 12 According to some embodiments of this disclosure, wild-type (WT) Salmonella typhimurium SL1344 strain (QT1573) and genetically modified Salmonella typhimurium SL1344 strain Δ are used. glmS- Δ pstSCA- pSLT:: glmS + (QT6282) Non-restrictive color Kaplan-Meier survival analysis of mice after challenge. Mortality was monitored daily for six days after challenge in all mice. The mortality rate of the WT strain was 60%, and there were no deaths in the group infected with the mutant genetically modified strain.
[0032] Figures 13A to 13C This is a non-limiting color graphic representation of bacterial counts present in the corresponding liver, spleen, and cecum of infected C57BL / 6 mice. According to some embodiments of this disclosure, a 6.10 x 10⁻⁶ pixel is used. 7 CFU of Salmonella typhimurium SL1344 (QT1573) and 9.10 x 10 7 CFU-modified Salmonella typhimurium SL1344 strain Δ glmS- Δ pstSCA- pSLT:: glmS + (QT6282) mice were infected. Results are reported as CFU per g of organ. Results are shown as mean ± SEM count of CFU per organ weight. The nonparametric Kruskal-Walis test was used to evaluate the Δ between the group challenged with WT QT1573 and the group challenged with the mutant genetically modified Salmonella typhimurium SL1344 strain. glmS- Δ pstSCA- pSLT:: glmS + (QT6282) Statistical differences between pairs of groups challenged with the virus.
[0033] Figure 14A and Figure 14B It is a lack of various things glmS and pstSCANon-limiting color images of a clone of *Salmonella typhimurium* SL1344. According to some embodiments of this disclosure, the clone could not grow on M9 medium containing BCIP (50 μg / mL) without NAG. Figure 14A However, it grows well on M9 medium containing NAG (250 μg / mL) and BCIP (50 μg / mL). Figure 14B This growth diagram confirms that the clone has destructive properties. glmS The gene, and therefore the auxotroph for NAG. A single clone was deposited in each quadrant of the M9 plate.
[0034] Figure 15 According to some embodiments of this disclosure, NAG-deficient organisms were grown on M9 medium containing BCIP (50 μg / mL) without NAG. glmS and pstSCA And including those containing functionality glmS Non-restricted color images of a plasmid containing a gene modified from the enteric Salmonella typhimurium SL1344 bacterial sample (QT6282). This growth confirmation plasmid... glmS Genes saved the damaged glmS .
[0035] Figure 16 Based on non-limiting images of PCR products from some embodiments of this disclosure, *Salmonella typhimurium* SL1344 (SL1344 Δ) was identified. glmS Δ pstSCA The genomes of *Salmonella typhimurium* SL1344 (QT6282) and *Salmonella typhimurium* SL1344 (QT6282) are found in... glmS and pstSCA Gene deletion. The ladder used was Thermoscientific™ GeneRuler DNA Ladder Mix SM0331.
[0036] Figure 17 This is a non-restrictive image of the PCR product from the SL1344 clone of *Salmonella typhimurium* after five passages on an agar plate, according to some embodiments of this disclosure, to confirm the presence of pSLT plasmid. glmS-pstSCA Missing and glmS Genetic stability of insertion into pSLT plasmids. Using primers CMD3082 / 3083, in SL1344 Δ glmS Δ pstSCA A 2297 bp band was detected in both strain SL1344 and the QT6282, confirming that the deletion is stable. Using primers CMD3297 / 3298, the deletion was further investigated in WT strain SL1344 and the mutant gene-modified strain SL1344 Δ. glmS Δ pstSCA A 1212 bp band was detected, confirming that the pSLT plasmid does not contain [a specific type of plasmid]. glmS After one and five subcultures on agar plates, a 3981 bp band was observed in strain QT6282, confirming the maintenance of [the desired growth pattern]. glmS Inserted into the pSLT plasmid. The ladder used was Thermoscientific™ GeneRuler DNA Ladder Mix SM0331.
[0037] Figure 18 The following are color images of test tubes incubated at 37°C for 16 hours in NAG-free LB liquid medium containing BCIP (50 μg / mL): (A) control—no inoculum, (B) wild-type virulent pathogenic APEC, and (C) genetically modified Escherichia coli based on (B) virulent pathogenic APEC. This demonstrates that the genetically modified bacteria of this disclosure can be optically detected by staining of growth medium containing chromogenic markers.
[0038] Figure 19 This is a non-restriction image of the PCR product to confirm the insertion into the O7 mutant strain ( ΔglmS-pstSCA- pAPEC-1 ΔiucABCD ΔiroBCDE::glmS) pAPEC-1 in the genome glmS Stability was confirmed. Using primers iroB_glmS_FW (7) and iroE_glmS_Rv (8), a 2348 bp band was detected in the mutant O7 strain during 10 passages in agar, confirming the maintenance of stability. glmS Inserted into the pAPEC-1 plasmid. The ladder used was GeneRuler LadderMix (SM0331). D = days.
[0039] The accompanying drawings illustrate exemplary embodiments by way of example. It should be clearly understood that the descriptions and drawings are for illustrative purposes only and to aid understanding. They are not intended to be limiting of the invention. Detailed Implementation
[0040] The present invention is explained in more detail below. This description is not intended to be a detailed list of all the different ways in which the technology can be implemented or of all the features that can be added to the present invention. For example, features described with respect to one embodiment may be incorporated into other embodiments, and features described with respect to a particular embodiment may be removed from that embodiment. Furthermore, given the disclosure of this invention, numerous variations and additions to the various embodiments suggested herein will be apparent to those skilled in the art, and such variations and additions do not depart from the present invention. Therefore, the following description is intended to illustrate some embodiments of the present invention and is not intended to exhaustively list all permutations, combinations, and variations thereof.
[0041] Through research and development, the inventors have surprisingly and unexpectedly developed a composition comprising genetically modified bacteria, which are attenuated bacteria with a reduced risk of regaining virulence. For example, the inventors have developed a system and method for generating and preserving gene-damaged genes in virulent pathogens to produce genetically modified bacteria (attenuated bacteria).
[0042] In some embodiments, the genetically modified bacteria further include the disrupted expression of one or more bacterial virulence factors.
[0043] Advantageously, the systems and methods described herein do not require antibiotic markers to preserve gene damage.
[0044] Such systems and methods have yielded unexpected results. For example, in many cases, key bacterial virulence factors are encoded on virulence plasmids, and while inactivating such systems can provide an efficient method for generating genetically modified bacteria (as attenuated bacteria), the disadvantage of targeting the genes encoded by the plasmids lies in the potential for regaining virulence. Indeed, such genetically modified bacteria can regain virulence through conjugation transfer of virulence plasmids from the natural host flora and / or through the potential for genetic recombination leading to the reacquisition of inactivated genes or systems. The potential to reverse the virulence of genetically modified live bacteria into virulent ones is generally considered a significant limitation of the virulence factor genes encoded by the plasmids. Surprisingly, the inventors have found that the systems and methods described herein generate attenuated genetically modified bacteria with a reduced risk of regaining virulence. This is demonstrated by the retention of the attenuated phenotype despite multiple bacterial culture passages in the absence of antibiotic markers: this advantageous property is demonstrated even when the bacterial virulence factors are encoded on virulence plasmids.
[0045] Given the teachings and data presented in this application, the reader will readily understand that the methods and systems described herein can be used to obtain genetically modified bacteria from any virulent (pathogenic) parent bacteria containing a virulence plasmid. For example, from any virulent (pathogenic) bacteria containing a virulence plasmid present in a pathogenic wild-type field strain. The systems and methods described herein represent a platform technology for generating genetically modified bacteria (i.e., attenuated bacteria).
[0046] The following paragraphs discuss bacterial characteristics, which also apply to the genetically modified bacteria described herein and to the virulence (pathogenicity) parent bacteria used to create genetically modified bacteria.
[0047] In some embodiments, the bacteria may be Gram-negative bacteria.
[0048] In some embodiments, the bacteria may belong to the Enterobacteriaceae family, which comprises a group of Gram-negative, rod-shaped, facultative anaerobic bacteria found in soil, water, plants, and animals, and frequently appear as pathogens in vertebrates.
[0049] As used herein, the term "Gram-negative bacteria" includes, but is not limited to, any of the following bacteria: *Aeromonas salmonicida*, *Aeromonas hydrophila*, *Aeromonas veronii*, *Anaeromyxobacter dehalogenans*, *Bordetella bronchiseptica*, *Bordetella parapertussis*, *Bordetella pertussis*, *Bradyrhizobium japonicum*, *Burkholderia cenocepacia*, *Burkholderia cepacia*, *Burkholderia mallei*, *Burkholderia pseudomallei*, *Chlamydia muridarum*, and *Chlamydia trachomatis*. Chlamydia trachmoatis, Chlamydophila abortus, Chlamydia pneumoniae, Chromobacterium violaceum, Citrobacter rodentium, Desulfovibrio vulgaris, Edwardsiella tarda, Endozoicomonas elysicola, Erwinia amylovora, Escherichia albertii, Escherichia coli, Lawsonia intracellularis, Mesorhizobium loti, Myxococcus xanthus, Pantoea agglomerans, Photobacterium damselae, Photorhabdus luminescens, Photorabdus* *Pseudoalteromonas spongiae*, *Pseudomonas aeruginosa*, *Pseudomonas plecoglossicida*, *Pseudomonas syringae*, *Ralstonia solanacearum*, *Rhizobium sp*, *Salmonella enterica* and other *Salmonella* species, *Shigella flexneri* and other *Shigella* species, *Sodalis glossinidius*, *Vibrio alginolyticus*, *Vibrio azureus*, *Vibrio campellii*, *Vibrio...* Vibrio caribbenthicus, Vibrio harvey, Vibrio parahaemolyticus, Vibrio tasmaniensis, Vibrio tubiashii, Xanthomonas axonopodis, Xanthomonas campestris, Xanthomonas oryzae, Yersinia enterocolitica, Yersiniapestis, and Yersinia pseudotuberculosis.
[0050] In some embodiments, the bacteria may be at least one of Escherichia coli, Shigella, Edwardsiella, Salmonella, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Morganella, Providencia, and Yersinia.
[0051] In some embodiments, the bacteria may be Salmonella or Escherichia coli.
[0052] In some embodiments, the virulent (pathogenic) parent bacterium is avian pathogenic Escherichia coli (APEC), a subgroup of Escherichia coli strains that cause disease in poultry. APEC infection can lead to respiratory diseases, septicemia, and other health problems in birds, significantly impacting the poultry industry.
[0053] In some implementations, the systems, methods, and genetically modified bacteria described herein offer one or more of the following technical advantages.
[0054] For example, the systems and methods described herein provide means for generating and preserving genetically modified bacteria without the need for selectants such as antibiotics. This method offers the possibility of using the genetically modified bacteria described herein in environments where selection using chemical supplements is impractical or undesirable, such as in certain animal or human applications (such as live vaccines or live therapeutic payloads), for use in the environment, or for use in certain industrial processes. This method also reduces manufacturing costs associated with antibiotics, waste treatment, and disposal. Furthermore, this method addresses the current trend in the agricultural and medical industries aimed at reducing antibiotic use due to the potential risk of increased resistance from microorganisms to antibiotics released into the environment.
[0055] For example, the genetically modified bacteria described herein lack antibiotic selection markers that can contaminate the environment, cause side effects in the host, or trigger harmful responses, particularly during vaccination or treatment load procedures. The methods, systems, and genetically modified bacteria described herein aim to eliminate potentially harmful environmental genes, such as antibiotic resistance genes, from the final recombinant organism.
[0056] For example, the systems, methods, and genetically modified bacteria described herein can provide constitutive expression of at least one target gene introduced into bacteria without the need for selectors (such as antibiotics), and can also provide visual identification of genetically modified bacteria by inoculating bacteria in growth media in the presence of a chromogenic substrate of alkaline phosphatase.
[0057] For example, the systems and methods described herein provide for the generation of genetically modified bacteria with stable mutations in bacterial virulence factors and a reduced risk of reversal. For example, the inventors have successfully demonstrated at least 5 and at least 10 mutations (see...) Figure 19 Mutual stability during bacterial passage. This reversal provides an opportunity to use genetically modified bacteria for various applications, such as live vaccines, live immunogenic compositions, or live therapeutic payloads, for example, for use in animals or humans, by reducing the risk of toxicity.
[0058] For example, the systems, methods, and genetically modified bacteria described herein can provide low-cost, safe, and efficient live vaccines, live immunogenic compositions, or live therapeutic payloads that can be administered to animals or humans using practical and cost-effective methods.
[0059] Systems and Methods 1. Chromosomal damage In some embodiments, the system includes bacteria with disruptions in chromosomal genes encoding proteins required for the synthesis of essential bacterial components. In other words, when bacteria include such disruptions, the bacteria will require an exogenous form of this essential component to grow and / or survive—that is, the bacteria are auxotrophic for this essential component. Such bacteria are also referred to herein as auxotrophic bacteria. Such genes are also referred to herein as auxotrophic genes.
[0060] Since the system can be used within the context of platform technologies for generating multiple genetically modified bacterial strains, it can include multiple bacterial strains, each of which includes chromosome disruption in a corresponding auxotrophic gene. In some embodiments, the auxotrophic gene may be the same auxotrophic gene across all bacterial strains on a given platform.
[0061] The bacteria described in this article are typically derived from corresponding pathogenic bacteria containing virulence plasmids. For example, from pathogenic wild-type field bacterial strains.
[0062] In some embodiments, the bacteria described herein have disruptions in more than one chromosomal gene. For example, disruptions in auxotrophic genes and one or more genes involved in phosphate regulation.
[0063] In some embodiments, the bacteria described herein disrupt multiple genes involved in phosphate regulation. For example, in the phosphate transport system (… pst In one or more genes of the operon.
[0064] In some embodiments, the auxotrophic gene and the one or more genes involved in phosphate regulation are consecutive chromosomal genes.
[0065] In some embodiments, the disruption can be performed using any suitable genetic engineering technique in molecular biology that modifies the genome of a living organism; i.e., chromosome disruption can include DNA insertion, deletion, modification, or substitution. For example, the disruption can be performed using any genome editing technique known in the art, such as, but not limited to, techniques involving polymerase chain reaction (PCR), homologous recombination, transposons, CRISPR gene editing, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), etc.
[0066] In some implementations, the disruption is a chromosomal deletion. For example, the deletion of the auxotrophic gene and / or at least a portion of one or more genes involved in phosphate regulation.
[0067] In some implementations, the disruption is a chromosomal deletion of the entire auxotroph gene.
[0068] In some implementations, the disruption is a one-step deletion resulting in a chromosome deletion, wherein the auxotrophic gene and one or more genes involved in phosphate regulation are deleted via a single genome editing event. For example, a one-step deletion can be performed on consecutive chromosomal genes using homologous recombination.
[0069] 2. Deficiency genes In some embodiments, the auxotrophic gene can be any suitable auxotrophic gene. For example, it can be a gene selected from those involved in cell wall synthesis, amino acid synthesis, nucleic acid synthesis, cofactor synthesis, coenzyme synthesis (e.g., FAD, NAD), etc.
[0070] In some embodiments, the auxotrophic gene is required for the synthesis of peptidoglycan in the bacterial cell wall.
[0071] In some embodiments, the auxotrophic gene is glmS Gene.
[0072] glmS The gene encodes the enzyme glutamine-fructose-6-phosphoamyltransferase (GFAT), which catalyzes the formation of glucosamine-6-phosphate (GlcN6P), essential for cell wall biosynthesis. GFAT includes the enzyme corresponding to Enzyme Committee number EC 3.5.99.6 and is necessary for the de novo bacterial production of N-acetylglucosamine (NAG).
[0073] exist glmSBacteria with genetic defects cannot grow and / or survive without supplementation of NAG or glucosamine (Sarvas M (1971) J Bacteriol 105: 467-471; Wu et al., J Bacteriol 105:455-466). This is because such bacteria cannot produce an endogenous reserve of NAG. Once any exogenous NAG is depleted, cell lysis and death occur, as NAG is a key building block of peptidoglycan, a component of the bacterial cell wall. NAG is also a component of the lipid A core of bacterial lipopolysaccharide.
[0074] Therefore, in glmS Mutant bacteria with disrupted genes are auxotrophic for NAG or glucosamine.
[0075] 3. Genes involved in phosphate regulation In some embodiments, the one or more genes involved in phosphate regulation include phosphate transport system operons ( pst One or more genes of an operon.
[0076] pst Operons encode high-affinity inorganic phosphate transporter systems found in many bacterial species, including Gram-positive and Gram-negative bacterial species such as Escherichia coli, Salmonella, Streptomyces lividans, and Bacillus subtilis. pst The operon comprises a series of genes encoding four Pst proteins (namely PstS, PstC, PstA, and PstB). Two copies of PstB (PstB1 and PstB2) exist in Bacillus subtilis.
[0077] Streptomyces and most other bacteria pst The operon is organized as an ATP-binding cassette (ABC) containing four proteins. The Pst system in *E. coli* has been characterized to perform two functions: (i) transport of inorganic phosphate and (ii) negative regulation of a phosphate regulator (a complex of 20 proteins primarily associated with organic phosphate transport). These two functions are believed to be unrelated because the repressibility of the phosphate regulator depends on the intact structure of the Pst system rather than the transported inorganic phosphate. pst Another gene of the operon phoU It produces proteins that participate in the negative regulation of the Pho regulator.
[0078] In some implementations, the embodiments described herein pst Damage in the manipulator can include pst Disruption in one or more genes of the operon, preferably disruption in multiple genes of the pst operon. For example, as described herein. pstDamage in the manipulator includes from pstS , pstC , pstA and pstB Disruption in one or more selected genes, preferably from pstS , pstC and pstA Disruption in one or more selected genes, and more preferably pstS , pstC and pstA Damage to genes.
[0079] pst Disruption of the operon leads to the deregulation of the phosphate regulator and constitutive expression of genes under the control of PhoB-regulated promoters. This constitutive expression capability provides the technical effect that the gene-modifying bacteria described herein can constitutively express any gene (i.e., endogenous or recombinant) under the control of a PhoB-regulated promoter, because these gene-modifying bacteria... pst The operon contains disruption. When such genes are under the control of a PhoB-regulated promoter, this can allow overexpression of the endogenous gene or constitutive expression of the exogenous (recombinant) target gene.
[0080] In some embodiments, the genetically modified bacteria described herein further include a recombinant target gene for delivering a therapeutic payload. For example, the recombinant target gene may be present in a rescued DNA molecule, as described later herein.
[0081] In some embodiments, the therapeutic payload includes a therapeutic gene or a gene encoding an antigen.
[0082] In some embodiments, the recombinant target gene for delivering the therapeutic payload is under the control of a PhoB-regulated promoter. When the genetically modified bacteria have disrupted... pst When the operon is activated, the recombinant target gene can be constitutively expressed.
[0083] In some embodiments, the constitutive expression of gene-modified bacteria described herein phoA The gene encodes alkaline phosphatase. This is because... phoAThe gene is under the control of a PhoB-regulated promoter. Therefore, disruption of the pst operon leads to constitutive expression of PhoA. Advantageously, constitutive expression of PhoA allows for the direct identification of gene-modified bacteria under specific conditions. For example, specific conditions may include growing bacteria in a growth medium supplemented with a chromogenic substrate for alkaline phosphatase. For example, the chromogenic substrate is disodium 5-bromo-4-chloro-3-indole phosphate (BCIP), alone or in combination with nitroblue tetrazolium (NBT), fast red-naphthol, p-toluidine 6-chloro-3-indole phosphate (salmon phosphate), or p-toluidine 5-bromo-6-chloro-3-indole phosphate (fuchsin phosphate). Growth of bacteria on a growth medium supplemented with a chromogenic substrate for alkaline phosphatase (e.g., growth medium plates) results in the production of colored colonies (e.g., deep blue when using BCIP), thus providing a direct visual identification method.
[0084] In some implementations... pst The disruption of the operon provides a method for identifying bacteria exhibiting the disruption described herein. This is because in it... pst In bacteria with inactivated / deficient operon, the pho regulator is constitutively expressed. Therefore, even under high phosphate conditions, bacteria overexpress alkaline phosphatase, which can provide a means of detecting bacteria. The method may include obtaining samples suspected of containing [the enzyme / phoregonic enzyme]. pst A sample of bacteria with disrupted operon is obtained by inoculating the sample into a growth medium (e.g., a plate or liquid broth) supplemented with a chromogenic substrate for alkaline phosphatase to obtain an inoculated growth medium. The method then includes incubating the inoculated growth medium under bacterial growth conditions and identifying the presence of bacteria with disrupted operon by the presence of a signal from the chromogenic substrate. This identification may further include identifying individual colonies when grown on a plate.
[0085] Unbound by any theory, the inventor is unaware of any publicly available literature that discloses the destruction of one or more [other methods / methods]. pst Genes are used to identify genetically modified bacteria by providing simple differential phenotypes and / or as a means of generating strains with constitutively expressed genes under the control of a PhoB-regulated promoter.
[0086] 4. DNA rescue molecules In some embodiments, the system further includes a DNA rescue molecule containing a functional copy of a gene encoding a protein required for the synthesis of an essential component (i.e., a functional copy of an auxotroph gene). The mutant bacteria described herein, when carrying the DNA rescue molecule (i.e., as recombinant bacteria), can grow and / or survive when cultured in the absence of the essential component.
[0087] In some embodiments, the DNA rescue molecule is a nonchromosomal genetic element.
[0088] Advantageously, the DNA rescue molecule can be configured to selectively retain itself due to the presence of a functional auxotrophic gene therein. This facilitates selective retention of the DNA rescue molecule when the mutant bacteria are grown in a culture medium (including in vivo) without supplementation of essential auxotrophic elements. Thus, the retention of this DNA rescue molecule is achieved without the use of antibiotic resistance genes.
[0089] DNA rescue molecules containing a functional copy of an auxotrophic gene can be introduced into bacteria using any suitable technique known in the art. For example, electroporation, transformation, transduction, or conjugation can be used. These techniques enable the introduction of DNA rescue molecules into bacteria, allowing the functional gene to compensate for the damaged auxotrophic gene. Suitable techniques are known in the art and will not be described further here.
[0090] In some embodiments, the DNA rescue molecule may include a site that allows insertion of one or more recombinant target genes. For example, the target gene may be used to deliver a therapeutic payload to a host.
[0091] For example, the DNA rescue molecule may include a multiple cloning site (MCS) or a polymerase linker having a restriction enzyme site for cloning a DNA molecule therein. For example, the one or more recombinant target genes may include therapeutic genes, genes encoding antigens, biosensors, enzymes, antibodies, etc. For example, the target gene may be operatively linked to and controlled by a PhoB-regulated promoter, i.e., for constitutive expression in the genetically modified bacteria described herein.
[0092] For example, the DNA rescue molecule may encode a target protein that provides a therapeutic benefit to the host. This therapeutic benefit may derive from the protein's ability to regulate physiological processes, correct genetic defects, or combat pathogenic conditions within the host. In such embodiments, live genetically modified bacteria act as live therapeutic payloads, delivering the encoded protein directly to host cells or tissues in a targeted and sustained manner. The therapeutic protein may include enzymes, cytokines, hormones, or other bioactive molecules designed to address specific medical conditions. Furthermore, genetically modified bacteria can be engineered to express therapeutic proteins in response to environmental or host-specific cues, thereby enhancing precision and reducing off-target effects. This approach enables bacteria to act as dynamic delivery systems, providing a new platform for treating a variety of diseases, including genetic disorders, metabolic conditions, and infectious diseases.
[0093] In some embodiments, the bacteria can deliver encoded proteins in a targeted manner through a number of engineered mechanisms or natural behaviors, such as tissue tropism (e.g., a natural affinity for a particular tissue or cell, such as preferential colonization of the gut, lungs, or tumors, allowing targeted delivery of therapeutic proteins to these regions), surface display of target molecules (e.g., expression of ligands, peptides, or antibodies on the bacterial surface that selectively bind to receptors on target cells), environmental triggers (e.g., bacteria can be programmed to activate the expression and release of therapeutic proteins in response to specific environmental conditions, such as pH changes, hypoxia, or the presence of certain metabolites), genetic switches and induction systems (e.g., bacteria can be equipped with genetic circuits that restrict protein expression to specific conditions or tissues), encapsulation of preparations (e.g., bacteria can be encapsulated in delivery systems, such as hydrogels or nanoparticles, to guide them to specific tissues), and so on.
[0094] In some embodiments, the DNA rescue molecule is configured to disrupt the expression of one or more bacterial virulence factors.
[0095] For example, the DNA rescue molecule may be configured to disrupt one or more bacterial genes involved in one or more virulence pathways. For example, the one or more bacterial genes involved in one or more virulence pathways may encode, but are not limited to, transcription factors (i.e., sequence-specific DNA-binding proteins required to regulate gene expression) that regulate the expression of the corresponding bacterial virulence factor, and RNA-binding proteins (e.g., proteins generated by...) that regulate the stability and / or degradation of messenger RNA encoding the corresponding bacterial virulence factor. hfq Gene-encoded Hfq proteins (also known as HF-I proteins), etc.
[0096] For example, the DNA rescue molecule may be configured to disrupt one or more bacterial virulence genes encoding corresponding bacterial virulence factors. Non-limiting examples of bacterial virulence genes will be discussed later in this document.
[0097] In some embodiments, the DNA rescue molecule may take the form of a plasmid vector. For example, the plasmid vector may be a microplasmid, which is typically a small, simplified plasmid designed to reduce unnecessary sequences and enhance efficiency, or a conventional plasmid that includes a wider range of regulatory elements and features. These plasmid vectors may carry additional elements, such as promoters, enhancers, or terminators, to facilitate gene expression and selection in the host organism.
[0098] For example, when the DNA rescue molecule is in plasmid vector form, it can be configured to cause selective loss of a bacterial virulence plasmid containing one or more bacterial virulence genes encoding a bacterial virulence factor. For example, the selective loss mechanism of a bacterial virulence plasmid containing one or more bacterial virulence genes encoding a bacterial virulence factor can be achieved through a known plasmid incompatibility mechanism. In other words, the DNA rescue molecule can contain a replication origin incompatible with one of the bacterial virulence plasmids present in a virulent pathogen, thereby causing selective loss of that virulence plasmid. This selective loss is independent of antibiotic markers because the DNA rescue molecule contains a functional copy of an auxotrophic gene. This selective loss of a bacterial virulence plasmid containing one or more bacterial virulence genes encoding a bacterial virulence factor generates the genetically modified bacteria described herein.
[0099] In non-restrictive implementations of APEC, Salmonella, and many other Enterobacteriaceae, most virulence plasmids are single-copy (one per cell) and contain an origin of replication similar to the F-plasmid. Other plasmids with low copy numbers can also be eliminated over time by replacing them with recombinant plasmids selected for survival under specific growth conditions (i.e., when the essential compounds required for bacterial viability by the strain are auxotrophic). When introducing coding... glmS When rescuing plasmids, the original plasmid is lost when cells are grown in the absence of NAG because the two plasmids have the same incompatibility set and encode... glmS The plasmid was chosen because it allows bacterial cells to grow in the absence of NAG.
[0100] In some implementations, the DNA rescue molecule in plasmid form may be based on a bacterial virulence plasmid. In this case, the bacterial virulence plasmid may be modified to disrupt one or more bacterial virulence genes encoding bacterial virulence factors. Such disruption in one or more bacterial virulence genes encoding bacterial virulence factors may include mutations, insertions, or deletions, as discussed elsewhere.
[0101] In some implementations, the DNA rescue molecule may take the form of a DNA box.
[0102] For example, when a DNA rescue molecule takes the form of a DNA cassette, it can be configured to cause the selective loss of one or more bacterial virulence genes encoding bacterial virulence factors. This can be achieved, for example, by inserting the DNA cassette into one or more bacterial genes involved in one or more virulence pathways and / or into one or more bacterial virulence genes encoding one or more bacterial virulence factors. This can be achieved through basic allelic exchange using methods such as those based on... sacBMethods such as suicide vectors (e.g., pMEG) are used. Double crossover results in the introduction of auxotrophic genes present on DNA rescue molecules into one or more virulence genes, thereby producing the damage described herein.
[0103] In some embodiments, the plasmid vector is a copy of a bacterial virulence plasmid that has been modified by inserting a functional copy of an auxotrophic gene at a DNA location corresponding to one or more virulence genes present in the bacterial virulence plasmid.
[0104] 5. Bacterial virulence genes In some embodiments, the genetically modified bacteria include disruption of one or more bacterial virulence genes encoding one or more bacterial virulence factors commonly found in virulent pathogens.
[0105] For example, the one or more bacterial virulence genes may be one or more genes from the siderophore system. Siderophores are low molecular weight (500-1,500 Da) high-affinity iron chelates used to dissolve and transport ferric iron into bacterial cells. In the extracellular environment, secreted siderophores form soluble iron-siderophore complexes with ferric iron. These soluble iron-siderophore complexes are actively transported into the bacterial cell via specific outer membrane receptors, whereupon ferric iron is released and reduced to ferrous iron, which is then available for cellular use. Siderophores are essential not only for the growth of most pathogens but also play important roles in non-ferrous metal transport, defense against oxidative stress, antibiotic activity, interspecies interactions, and virulence (e.g., Kramer et al., (2020). Bacterial siderophores in community and host interactions). Nat. Rev. Microbiol. 18, 152-163).
[0106] In some embodiments, the one or more bacterial virulence factors are derived from... iuc Operators and / or iro One or more genes are encoded by the operon.
[0107] iuc Operators include iucABCD Gene. iucABCDThe gene is required for the synthesis of the iron-chelating siderophore cyclobacin. Cyclobacin is a citrate-hydroxamic acid siderophore produced by many pathogenic bacteria. The cyclobacin operon encodes four biosynthetic enzymes (IucABCD) and a transmembrane transporter (IutA) involved in the biosynthesis and transport of cyclobacin siderophores. Cyclobacin is known to promote bacterial virulence in many bacteria, including Escherichia coli, Vibrio, Salmonella, and Shigella, by mediating iron acquisition during infection (Sheldon et al., (2016). Iron acquisition strategies of bacterial pathogens). Microbiol. Spectr. 4(2)).
[0108] iro Operators include iroBCDEN Gene. iroBCDEN The gene encodes a salmochelin siderophore system present in intestinal Salmonella and some extraintestinal pathogenic Escherichia coli (ExPEC) strains. Avian pathogenic Escherichia coli (APEC) strains are a subset of ExPEC strains associated with respiratory infections and septicemia in avian species, particularly poultry. Iron-chelated siderophore salmochelins are known to enhance bacterial virulence by mediating iron uptake during infection (e.g., Caza et al., Infect Immun. 2008 Aug; 76(8): 3539–3549).
[0109] In some embodiments, the DNA rescue molecule can be configured to disrupt iuc The expression of the operator, such as the destruction from iucABCD One or more genes.
[0110] For example, DNA rescue molecules in plasmid vector form can be configured to result in the presence of functional DNA. iuc Selective loss of the bacterial virulence plasmid from the operon. The DNA rescue molecule can be further configured to be free of... iuc A functional copy of the operator, or one that does not contain any source from... iucABCD One or more genes.
[0111] For example, a box-form DNA rescue molecule can be configured to insert into iuc In the manipulator, that is, by inserting it to disrupt the source from iucABCD One or more genes.
[0112] In some embodiments, the DNA rescue molecule can be configured to disrupt iro The expression of the operator, such as the destruction from iroBCDEN One or more genes.
[0113] For example, DNA rescue molecules in plasmid vector form can be configured to result in the presence of functional DNA. iro The selective loss of the bacterial virulence plasmid in the operon. The plasmid vector can be further configured to be free of... iro A functional copy of the operator, or may not contain any from iroBCDEN One or more genes.
[0114] For example, a box-form DNA rescue molecule can be configured to insert into iro In the manipulator, that is, by inserting it to disrupt the source from iroBCDEN One or more genes.
[0115] For example, DNA rescue molecules in plasmid vector form can be configured to result in the presence of functional DNA. iuc Operators and functionality iro Selective loss of the bacterial virulence plasmid from the operon. The DNA rescue molecule can be further configured to be free of... iuc Operators and iro A functional copy of the operon. The resulting genetically modified bacteria will have even greater virulence reduction compared to genetically modified bacteria with a single disruption in the siderophore system.
[0116] In some embodiments, the plasmid vector is a copy of a bacterial virulence plasmid that has been modified by inserting a functional copy of a auxotroph gene at a DNA location corresponding to one or more genes of the siderophore system in the bacterial virulence plasmid.
[0117] In some implementations, the box-form DNA rescue molecule can be configured to disrupt iuc and iro Both operons. The resulting bacteria will also have even greater reduced virulence compared to bacteria with a single disruption in the siderophore system.
[0118] In some embodiments, the systems and methods described herein disrupt the expression of two pathogen-associated siderophore synthesis systems (i.e., genes for salmonid and aerobicin siderophores). This disruption can be achieved by deleting or mutating the aerobicin synthesis operon gene ( iucABCD ) and through the deletion or mutation of genes for salmonellin synthesis and utilization ( iroBCDE In this type of implementation, modifications that inactivate the pathogen-specific siderophore synthesis system (encoding salmonidin and aerobicin) prevent the bacterial strain from persisting in the host's extraintestinal tissues.
[0119] Because the siderophore outer membrane receptors IutA and IroN, required for aerobicin uptake, are upregulated during respiratory and bloodstream infections and are surface-expressed pathogen-specific antigens, the genes encoding these receptors are preserved in the systems and methods described herein. The genetically modified bacteria described herein (particularly the genetically modified *Escherichia coli* described herein) strongly express these genes under low-iron conditions.
[0120] Importantly, the genetically modified strains described in this article can still grow well in vitro under low iron conditions because they produce and can take up the siderophore enterobacterin. This is, for example, the only siderophore present in many *E. coli* strains that reside symbiotically in the intestines of mammals or birds. Although enterobacterin is an excellent siderophore in vitro or in environmental niches (such as soil), it is less effective for iron uptake during host infection because host defense proteins such as lipid transporter 2 (complexin) chelate this siderophore, preventing it from being used by bacteria for iron uptake in the host.
[0121] The capture of enterobactin via lipid transport protein 2 (ferritin) has also been shown to induce a host inflammatory response, and its production can act as a signal to the host immune system (Nelson AL, Ratner AJ, Barasch J, Weiser JN. Interleukin-8 secretion in response to aferric enterobactin is potentiated by siderocalin. Infect Immun. 2007 Jun; 75(6):3160-8. doi:10.1128 / IAI.01719-06. Epub 2007 Apr 9.PMID: 17420239).
[0122] Therefore, the enterotoxin siderophore system can provide some bacterial growth in some tissues (such as the intestine), but its ability to isolate iron in extraintestinal tissues or respiratory mucosal surfaces is very limited, in which host defense lipid transport protein 2 can neutralize this siderophore and thus inhibit bacterial growth.
[0123] 6. Immunogenic compositions—vaccines In some embodiments, the genetically modified bacteria can be administered (e.g., in the form of an immunogenic composition or vaccine) to a host capable of initiating, inducing, or stimulating an immune response. Such hosts can encompass a wide range of vertebrate hosts, such as mammals (including domestic, agricultural, laboratory animals, and humans), various bird species (including domestic and agriculturally important birds such as chickens, ducks, turkeys, geese, pheasants, quails, pheasants, pigeons, etc.), and various fish species.
[0124] In some embodiments, the vaccines disclosed herein comprise live, non-virulent genetically modified bacteria, which are particularly advantageous for vaccination of vertebrate hosts susceptible to diseases caused by correspondingly virulent (pathogenic) bacteria. The genetically modified bacteria used in the vaccines are auxotrophic, possessing irreversible, non-leaking mutations in the biosynthetic pathway. These mutations result in essential components that are not available in sufficient quantities in the animal to be vaccinated, allowing the genetically modified bacteria to proliferate significantly. Therefore, the vaccine strains can be cultured on media supplemented with the essential components and remain viable after introduction into the host until cleared by the host's immune response. However, these bacteria will not be able to proliferate significantly due to the unavailability of the biosynthetic pathway products in the host. Despite this limitation, the genetically modified bacteria retain their native antigenic properties, enabling them to stimulate an effective immune response.
[0125] In addition to auxotrophic mutations that restrict the proliferation of bacteria within the host body that are used to administer vaccines, genetically modified bacteria used as live vaccines also contain genetic markers to facilitate differentiation from other bacteria of the same species, whether wild-type strains or other live vaccine strains. Suitable genetic markers include, for example... phoA Constitutive expression of genes provides a basis for identification via chromophores such as BCIP. Such markers are particularly useful in distinguishing between vaccine strains and wild-type strains, especially in cases where vaccine recipients have been exposed to bacteria before establishing vaccine-induced immunity.
[0126] Unlike other live vaccine formulations, this invention explicitly identifies the mechanism leading to the loss of virulence in genetically modified bacteria. Compared to other live vaccine strains that become non-toxic through alterations to their lipopolysaccharide structure, the vaccine strains described herein retain essentially unchanged O-antigen properties and other surface antigens associated with virulence and immunity, such as major outer membrane proteins. Therefore, these vaccines are able to induce the production of anti-O antibodies, which are considered a key component of immunity induced by vaccination. The vaccine strains are expected to persist in the host for an extended period, typically several weeks, thereby enhancing the immune response by continuously stimulating the host immune system until the immune system has cleared all bacterial organisms.
[0127] In some embodiments, the genetically modified bacteria, the immunogenic composition comprising them, or the vaccine may be administered for preventative or therapeutic purposes.
[0128] In some embodiments, the genetically modified bacteria are alive when administered to a host as an immunogenic composition or vaccine. Therefore, live genetically modified bacteria can be formulated into live immunogenic compositions or live vaccines.
[0129] In some embodiments, the immunogenic composition or vaccine containing the genetically modified bacteria can induce a protective immune response in animals against subsequent natural exposure to the corresponding virulent pathogen or experimental challenge with the corresponding virulent pathogen.
[0130] The methods of administering the immune compositions or vaccines described herein encompass well-known techniques within the expertise of those skilled in the art.
[0131] For example, the immunogenic compositions or vaccines described herein can be formulated for parenteral or enteral administration.
[0132] For example, the immunogenic compositions or vaccines described herein can be used for appropriate administration, such as oral, ocular, transdermal, transmucosal, intravenous, subcutaneous, intramuscular, intradermal, intraperitoneal, intracystic, intraspinal, intrasternal, intrapulmonary, intranasal, vaginal, rectal, intraocular, intrathecal, buccal (e.g., sublingual), respiratory, local, ingested, local delivery (e.g., via aerosol or transdermal), and similar methods.
[0133] For example, the immunogenic compositions or vaccines described herein can be used for appropriate administration, such as ocular (eye drops), pulmonary inhalation, nasal delivery, or respiratory delivery. “Nasal delivery” means that the immunogenic compositions or vaccines described herein are administered to a subject via the nose. “Pulmonary inhalation” means that the immunogenic compositions or vaccines described herein are administered to a subject via the airway of the nose or mouth, resulting in delivery of the immunogenic compositions or vaccines described herein to lung tissue and the interior of the lungs. Both nasal delivery and pulmonary inhalation can result in delivery of the immunogenic compositions or vaccines described herein to lung tissue and the interior of the lungs, and are also referred to herein as “pulmonary delivery.” “Respiratory delivery” means that the immunogenic compositions or vaccines described herein are administered to a subject via the subject’s respiratory system, resulting in delivery of the immunogenic compositions or vaccines described herein to the organs and tissues of the subject’s respiratory system. The organs and tissues of the subject’s respiratory system include, but are not limited to, the lungs or nose.
[0134] In some embodiments, the immunogenic compositions or vaccines described herein may be in the form of ready-to-use solutions for parenteral injection.
[0135] In some embodiments, the immunogenic compositions or vaccines described herein may be in the form of lyophilized, freeze-dried, spray-dried, or foam-dried compositions. For example, the immunogenic compositions or vaccines may be in powder form.
[0136] In some embodiments, the immunogenic compositions or vaccines described herein may be in the form of compositions designed to be reconstituted in physiologically acceptable solutions for administration via any suitable route.
[0137] In some embodiments, commercial packaging may include a composition and a physiologically acceptable solution in a separate container for reconstitution in the physiologically acceptable solution for administration via any suitable route. Such commercial packaging may further include instructions for use, mixing, or processing of the composition and the physiologically acceptable solution. Such commercial packaging may also further include a dispenser suitable for administering the reconstituted composition to animals.
[0138] In some embodiments, a physiologically acceptable solution may include one or more elements suitable for compositional reconfiguration for administration via any suitable route. For example, sterile water for injection is water that has been purified and sterilized to meet standards for injection use. For example, physiological saline (0.9% sodium chloride) is a solution containing a sodium chloride concentration similar to that of extracellular fluid in the body.
[0139] In some embodiments, the immunogenic composition or vaccine may further comprise pharmaceutically or veterinarily acceptable excipients, diluents, or carriers.
[0140] Pharmaceutically or veterinarily acceptable excipients, diluents, or carriers are well known to those skilled in the art. Examples include 0.9% NaCl solutions (saline) and buffers (e.g., phosphates, HEPES, etc.) used to maintain appropriate pH.
[0141] Details regarding dosage and volume are provided in the general description and can be determined by those skilled in the art through careful consideration of this disclosure and existing knowledge in the art, without excessive experimentation.
[0142] The required dose will vary depending on the antigenicity of the bacteria (or the antigens they express), and only a sufficient amount is needed to induce an immune response adequate to confer protection against the target pathogenic organism. The required dose can be easily determined through routine experiments.
[0143] For example, the initial vaccine dose for chickens weighing 40-50g at the time of administration could be 5 x 10 mg / kg per chicken. 6 CFU up to 5 x 10 8 CFU (CFU = Colony Forming Unit). For clarity, for a chicken weighing 40-50g, approximately 1-2 x 10⁻⁶ CFU / kg. 9The dose of CFU / Kg will correspond to 1 x 10 8 CFU dosage.
[0144] 7. Therapeutic Load System In some embodiments, the genetically modified bacteria described herein can be used as therapeutic payload systems, wherein bacteria are engineered to deliver therapeutic agents to host cells, organs, or tissues—a process known as “bactofection.” These therapeutic agents may include proteins, peptides, nucleic acids, small molecules, or other bioactive substances that provide therapeutic benefits. The bacteria act as a live delivery platform, capable of transporting these agents to specific tissues or cells within the host in a targeted and sustained manner.
[0145] Genetically modified bacteria can be engineered to carry DNA rescue molecules that encode target proteins for addressing specific medical conditions. For example, such proteins could include enzymes for correcting metabolic disorders, cytokines for regulating immune responses, and hormones for restoring physiological homeostasis. These proteins can be expressed by bacteria and released directly at their sites of action to provide local therapeutic effects while minimizing systemic side effects.
[0146] In some embodiments, the genetically modified bacteria can target solid tumors, resulting in a therapeutic effect in tumor-bearing subjects. In such cases, anaerobic bacteria are preferred. Without being bound by any theory, it is believed that various microenvironmental characteristics may favor the preferential proliferation and colonization of bacteria in tumors. For example, the hypoxic microenvironment present in necrotic regions of solid tumors can drive genetically modified bacteria to target solid tumors. For example, chemotactic compounds (e.g., aspartic acid, serine, citrate, ribose, or galactose) present in necrotic regions produced by resting cancer cells may be important contributing factors to bacterial chemotaxis towards tumors. For example, other unique microenvironmental characteristics found in solid tumors (such as aberrant neovascularization and local immunosuppression) are also considered to be factors involved in bacterial tumor targeting.
[0147] In some embodiments, the genetically modified bacteria are engineered for tissue-specific targeting. This may involve selectively binding to the expression of ligands or surface molecules of receptors present on the target tissue or cell type. For example, bacteria may be programmed to preferentially colonize tumors, inflamed tissues, or other lesion areas to ensure precise delivery of the therapeutic payload.
[0148] In some implementations, the delivery of the treatment can be controlled by environmental or host-specific cues. For example, bacterial genetic circuits can be engineered to activate the expression or release of therapeutic agents in response to environmental conditions such as pH, hypoxia, or specific metabolites. This ensures that the therapeutic payload is deployed only under appropriate conditions, thereby improving safety and efficacy.
[0149] The genetically modified bacteria can also employ secretion systems (such as type III, IV, or VI secretion systems) to deliver therapeutic proteins directly into the cytoplasm of host cells. This allows for highly efficient intracellular delivery of therapeutic agents, which is particularly beneficial in situations requiring intracellular regulation, such as genetic diseases or infections.
[0150] In some embodiments, the bacteria can be administered in multiple forms, including as part of a pharmaceutical composition. The composition may include physiologically acceptable carriers, excipients, or diluents suitable for routes of administration such as oral, intravenous, intranasal, or subcutaneous. For example, the bacteria may be encapsulated in a biocompatible matrix or nanoparticle formulation, which enhances stability and targeting while protecting the bacteria during delivery to the target site.
[0151] The dosage and administration regimen for therapeutic bacteria will depend on a number of factors, including the type of therapeutic agent, the condition being treated, and the specific needs of the host. Generally, the dosage should be sufficient to deliver an effective amount of the therapeutic agent to achieve the desired therapeutic outcome.
[0152] The genetically modified bacteria described herein as therapeutic payload systems offer a method for treating a variety of diseases, including but not limited to genetic disorders, metabolic diseases, cancer, and infectious diseases. By leveraging the inherent adaptability and targeting capabilities of bacteria, these systems provide a versatile and innovative platform for therapy.
[0153] 8. Genetically modified bacteria In a broader aspect, the inventors have developed genetically modified bacteria that exhibit an attenuated phenotype, which retain the genetic modifications and thus the attenuated phenotype without the need for antibiotic markers.
[0154] In some embodiments, the genetically modified bacteria include auxotrophic genes and one or more genes involved in phosphate regulation (such as phosphate transport systems). pst Chromosomal disruption in one or more genes of the operon. The genetically modified bacteria further include a DNA rescue molecule containing a functional copy of an auxotroph gene. The genetically modified bacteria have lost the ability to cause serious disease, but retain the ability to stimulate immunity, for example, against virulent pathogenic strains corresponding to the genetically modified bacterial strain.
[0155] The genetically modified bacteria may further include the disruption of one or more bacterial virulence factors.
[0156] Now refer to Figure 1A and Figure 1B To further explain the specific implementation methods of gene-modified bacteria and their manufacturing systems.
[0157] like Figure 1A and Figure 1B As shown, the chromosome phosphate transporter system ( pst (Manipulator) 100 and glmS Damage 150 in gene 200 results in the presence of the damaged gene. Pst and glmS The gene mutation is on chromosome 110. Disruption 150 can be achieved using a one-step deletion in genes 100 and 200 on consecutive chromosomes (as shown in the figure). Advantageously, the disrupted... glmS Gene 200 results in a conditionally lethal mutation, and bacterial cells cannot grow and / or survive without NAG supplementation. Advantageously, the disrupted... pst Operon 100 leads to the deregulation of the Pho regulator, resulting in constitutive production of genes under the control of the PhoB-dependent promoter.
[0158] like Figure 1B As shown, containing glmS DNA rescue molecules for functional copies of genes can be in the form of plasmid vector 250 or DNA cassette 350. Both plasmid vector 250 and cassette 350 show auxotrophic characteristics. glmS Functional copies of genes to compensate for damaged chromosomes. glmS Gene.
[0159] In some embodiments, the plasmid vector 250 or the cassette 350 glmS Genes can be generated in PhoB-dependent promoters or glmS Under the control of the gene's native promoter.
[0160] In some embodiments, plasmid vector 250 or cassette 350 may include sites that allow the insertion of foreign DNA genes. For example... Figure 1B As shown, this site can include a multiple cloning site (MCS). Examples of exogenous DNA genes are discussed elsewhere in this article.
[0161] 9. The actual implementation of gene modification in E. coli In some embodiments, pathogenic Escherichia coli strains can be modified according to the teachings described herein to obtain genetically modified Escherichia coli strains. For example, genetically modified Escherichia coli can be used as immunogenic compositions, therapeutic payloads, or vaccines. For example, immunogenic compositions or vaccines can be used against the aforementioned pathogenic Escherichia coli strains.
[0162] In some embodiments, the genetically modified bacteria, the immune compositions containing them, and the vaccines described herein can be used in the context of vaccinating animals.
[0163] For example, in the context of vaccinating poultry and agriculturally important birds such as chickens, turkeys, quails, and ducks.
[0164] For example, the genetically modified bacteria described in this article can be used to vaccinate avian species to target avian pathogenic Escherichia coli (APEC) infection and related diseases.
[0165] APEC-related diseases represent a significant impact on the poultry industry worldwide, including chickens and turkeys. In fact, APEC is often unintentionally maintained in poultry house environments through fecal contamination, allowing systemic infection to occur when large amounts of APEC enter the bloodstream via the respiratory or intestinal tract. Typically, bacteremia develops into septicemia and death, or the infection can spread to serous membranes, the pericardium, joints, and other organs. In birds, APEC commonly causes inflammation of the air sacs (air sacculitis), oviducts (salpingitis), and skin and muscle (cellulitis), all of which lead to tissue damage (i.e., lesions).
[0166] Typically, APEC and related diseases can cause significant economic losses to the poultry industry through factors such as mortality, failure to gain weight (also known as poor feed conversion ratio), hatchability, and / or egg production, septoxemia (the circulation of bacteria in the blood), cellulitis, broiler processing plant censure, or any combination thereof.
[0167] Typically, treatment of APEC and related diseases (such as avian colibacillosis) in the poultry industry requires the administration of antibiotics in feed or water. However, in recent years, there have been reports of high-frequency resistance to antibiotics such as tetracycline, kanamycin, neomycin, cefotaxime, streptomycin, and erythromycin. Many APEC strains are also resistant to multiple antibiotics. Widespread susceptibility to ampicillin and chloramphenicol has also been observed. In 2012 and 2013, the U.S. Food and Drug Administration issued Industry Guidance #209 and #213, recommending that the food production animal industry use antibiotics with caution. These documents discourage the use of antimicrobial growth promoters as part of a strategy set to combat antimicrobial resistance. In response to consumer demand, regulatory requirements, and scientific concerns, the U.S. broiler industry has shifted most of its production to an antibiotic-free (NAE) situation. The antibiotic-free system prohibits the use of all medically important antibiotics as antimicrobial growth promoters. For example, as of 2019, more than 50% of poultry in the United States was produced under NAE. Broilers in NAE environments are more susceptible to E. coli infection and other infections due to increased physiological stressors and a lack of sub-therapeutic antimicrobial agents.
[0168] In some embodiments, pathogenic Escherichia coli strains can be modified according to the teachings described herein to obtain genetically modified Escherichia coli strains, which can be used as immunogenic compositions, therapeutic loads, or vaccines. For example, immunogenic compositions or vaccines can be used against pathogenic Escherichia coli strains.
[0169] In some embodiments, the DNA rescue molecule described herein can be a plasmid vector based on the pAPEC-1 virulence plasmid (Mellata et al., PLoS One. 2009;4(1):e4232). For example, the DNA rescue molecule can be configured to disrupt the expression of one or more bacterial virulence genes by plasmid incompatibility with a bacterial virulence plasmid, such as the bacterial pAPEC-1 virulence plasmid. For example, the pAPEC-1 virulence plasmid-based DNA rescue molecule plasmid vector can be configured to include insertions into... iuc and / or iro Functional auxotrophic genes (such as those in one or more genes in the operon) glmS (genes), thereby repairing damaged chromosomes. glmS The genes resulted in the preservation of the DNA rescue molecular plasmid vector relative to the pAPEC-1 virulence plasmid.
[0170] In some embodiments, the genetically modified bacteria described herein can be any serotype of genetically modified APEC strains. Non-limiting examples of genetically modified APEC strains of serotype O7 are as follows: Figure 7B As shown in the image, this bacterium still expresses O antigen, fimbriae, LPS, etc., which are common antigens recognized by the immune system in response to infection. Figure 7B Chromosomes were also shown. glmS and pst Disruption in the operon, and a DNA rescue molecule in plasmid vector form based on the virulence pAPEC-1 plasmid. The DNA rescue molecule is shown to contain... glmS A functional copy of the gene, and without iuc Operators and iro Functional copy of the operator.
[0171] A non-limiting example of a genetically modified Escherichia coli (APEC) strain of serotype O7 is the strain deposited with the International Depository & Collections Authority of Canada (IDAC) on December 20, 2023, with accession number 201223-01.
[0172] As shown in the non-limiting example, the genetically modified O7 APEC deposited with accession number 201223-01 provides protective immunity against pathogenic O7 APEC strains in avian species.
[0173] 10. The actual implementation of genetically modified Salmonella Salmonella infection is a worldwide disease caused by bacteria belonging to the genus *Salmonella*. *Salmonella enterica* subspecies *Enterocera* is a Gram-negative bacterial pathogen. Known *Salmonella* pathogens include, but are not limited to, *Salmonella kentucky*, *Salmonella enteritidis*, *Salmonella heidelbergensis*, *Salmonella typhimurium*, and *Salmonella hadar*.
[0174] Serotypes of *Salmonella enteritidis* (SE) and *Salmonella typhimurium* are significant public health problems associated with the consumption of contaminated poultry and eggs. Chickens infected with these serotypes are often asymptomatic but shed the bacteria for an extended period, posing a risk to human health. Eggs are the primary vector for *Salmonella* transmission, with contamination occurring either externally through environmental exposure or internally through colonization of the reproductive tract of *Salmonella enteritidis*. Internal contamination that cannot be eliminated by sanitation measures is more likely to occur during egg formation than through penetration through the eggshell.
[0175] The EU's regulatory efforts have reduced the prevalence of Salmonella in poultry and eggs through vaccination and surveillance programs, including banning the use of antimicrobial agents and requiring vaccination in high-prevalence areas. Despite these measures, Salmonella remains a frequently reported zoonotic disease, with eggs still posing a significant risk of transmission.
[0176] In some embodiments, pathogenic Salmonella bacterial strains can be modified according to the teachings described herein to obtain genetically modified Salmonella bacterial strains, which can be used as immunogenic compositions, therapeutic loads, or vaccines. For example, immunogenic compositions or vaccines can be used against pathogenic Salmonella bacterial strains.
[0177] In some embodiments, the DNA rescue molecule described herein can be a plasmid vector based on the pSLT_SL1344 virulence plasmid (GenBank accession number HE654724). For example, the DNA rescue molecule can be configured to disrupt the expression of one or more bacterial virulence genes through plasmid incompatibility with bacterial virulence plasmids (such as the bacterial pSLT_SL1344 virulence plasmid). For example, the pSLT_SL1344 virulence plasmid-based DNA rescue molecule plasmid vector can be configured to include functional auxotrophic genes (such as... glmS (genes), thereby repairing damaged chromosomes. glmS The genes resulted in the preservation of the DNA rescue molecular plasmid vector relative to the pSLT_SL1344 virulence plasmid.
[0178] A non-limiting example of a genetically modified serotype of enteric Salmonella typhimurium is strain (QT6282) deposited at the Canadian International Depository (IDAC) on January 9, 2025, with accession number 090125-01.
[0179] in conclusion The methods and systems described herein have resulted in the generation of genetically modified *E. coli* and *Salmonella* bacteria, retaining the genetically modified phenotype without the need for antibiotic markers. The inventors believe that the methods and systems described herein can be used with any pathogenic bacteria containing a virulence plasmid. The methods and systems described herein represent a platform technology for generating genetically modified bacteria (such as genetically modified Gram-negative bacteria) without the need for antibiotics.
[0180] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. As used herein, and unless otherwise stated or required by context, each of the following terms shall have the following definition.
[0181] The term "recombinant bacteria" broadly refers to bacteria that have undergone genetic modification to introduce specific genes or DNA sequences into their genome (i.e., chromosomal DNA and plasmid DNA), resulting in the expression of new traits or the production of desired proteins.
[0182] A "mutation" is an alteration of a polynucleotide sequence, characterized by changing one or more nucleotide bases, inserting one or more nucleotides into the sequence, deleting one or more nucleotides from the sequence, or a combination of these.
[0183] "Genetic modification" refers to a state in which bacteria have been weakened from their wild-type state through some form of recombination or physical manipulation. This includes altering the bacterial genotype to reduce its ability to cause disease. However, the bacteria's ability to colonize and infect tissues and induce an immune response is preferably not significantly impaired.
[0184] The term "gene" broadly refers to any polynucleotide segment related to a biological function. A gene can encompass introns and exons, as seen in genomic sequences, or consist solely of coding sequences, as in cDNA, and regulatory sequences necessary for their expression. Furthermore, the term "gene" can refer to a nucleic acid fragment that expresses mRNA or functional RNA, encodes a specific protein, and includes regulatory sequences. Genes in bacteria typically do not have introns, and therefore, preferably, genes consist solely of coding sequences.
[0185] The term "conjugative transfer" refers to the process by which DNA is transferred from a donor bacterium to a recipient bacterium via specialized multiprotein complexes called conjugation apparatus. A prerequisite for conjugative transfer is a close contact between the cell surfaces of the interacting donor and recipient cells. In Gram-negative bacteria, this physical contact is established by complex extracellular filaments called sex pili.
[0186] The term "plasmid incompatibility" refers to the inability of two plasmids to coexist stably in the same host cell when they share the same replication mechanism or regulatory elements. This phenomenon is primarily determined by the replicon region, which encompasses the origin of replication (ori) and its associated regulatory components. When the ori sequences of two plasmids are identical or nearly identical, the plasmids typically compete for the same replication mechanism within the host, leading to incompatibility. However, small variations in the ori sequence, such as differences in one or more nucleotides, can provide a degree of flexibility depending on the nature of the change. Specifically, such nucleotide differences may alter the recognition of ori by the replication initiation protein, its interaction with host replication factors, or other regulatory mechanisms. If these differences do not significantly affect the plasmid replication system, the plasmids may remain incompatible. Plasmid compatibility is determined not only by the ori sequence but also by the specificity of the entire replication system, including the initiation protein and its interaction with the origin of replication. Plasmids employing different replication systems (such as those belonging to different incompatibility groups) can often coexist stably, even if their ori sequences show some similarity.
[0187] Expressions such as “defense against disease,” “protective immunity,” and “functional immunity” broadly refer to a response to a disease or condition induced by administration of one or more therapeutic compositions or combinations thereof. This response results in fewer harmful effects than would be expected in non-immunized subjects exposed to the disease or infection. Specifically, in vaccinated subjects, the severity of harmful effects from infection is reduced, mitigated, or potentially prevented.
[0188] In a broad sense, "immune response" refers to the cellular and / or antibody-mediated immune response developed in response to antigens in a composition or vaccine. A therapeutic or prophylactic immune response in the host enhances resistance to new infections and / or reduces the clinical severity of the disease.
[0189] "Pharmaceutical or veterinary acceptable carriers" broadly refer to solvents, dispersion media, coatings, adjuvants, stabilizers, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delay agents, etc. In some embodiments, stabilizers used for lyophilization are preferred.
[0190] "Therapeutic effective dose" broadly refers to the amount of live genetically modified bacteria or vaccine containing it that induces an immune response in a subject receiving the bacteria, sufficient to prevent or reduce signs or symptoms of disease caused by infection with a pathogen (such as bacteria), including adverse health effects or their complications. It can induce humoral or cell-mediated immunity, or both. An animal's immunogenic response to a live genetically modified bacteria or vaccine can be assessed indirectly, for example, by measuring antibody titers, lymphocyte proliferation assays, or directly by monitoring signs and symptoms after challenge with a wild-type strain. Protective immunity conferred by the live genetically modified bacteria or vaccine can be assessed by measuring, for example, a reduction in clinical signs (such as mortality, morbidity, body temperature, general physical condition, and overall health and performance). The therapeutically effective dose of live genetically modified bacteria or vaccine can vary depending on the specific live genetically modified bacteria or vaccine used or the condition of the subject and can be determined by those skilled in the art.
[0191] "Cellular immune response" or "cell-mediated immune response" is a response mediated by T lymphocytes or other leukocytes or both, and includes the production of cytokines, chemokines and similar molecules by activated T cells, leukocytes or both; or a T lymphocyte or other immune cell response that kills infected cells.
[0192] "Humoral immune response" refers to an antibody-mediated response. In a subject, "immune response" refers to the development of a humoral immune response, a cellular immune response, or both of humoral and cellular immune responses against live genetically modified bacteria or vaccines. Immune responses can typically be determined using standard immunoassays and neutralization assays, which are known in the art.
[0193] The “immunoprotective dose,” “immunoeffective dose,” or “effective dose to elicit an immune response” of genetically modified bacteria, immunogenic compositions, or vaccines is the amount that effectively induces an immunogenic response in a recipient. An immunogenic response may be sufficient for diagnostic purposes or other testing, or sufficient to prevent signs or symptoms of disease caused by pathogen infection, including adverse health effects or their complications. It may induce humoral immunity or cell-mediated immunity, or both. An immunogenic response in animals to an immunogenic composition may be assessed indirectly, for example, by measuring antibody titers, lymphocyte proliferation assays, or directly by monitoring signs and symptoms after challenge with a wild-type strain, while protective immunity conferred by a vaccine may be assessed by measuring, for example, a decrease in clinical signs (such as mortality, morbidity, body temperature, overall physical condition, and overall health and performance). Immune responses may include, but are not limited to, inducing cellular and / or humoral immunity. “Immunogenic” means eliciting an immune or antigenic response. Therefore, an immunogenic composition can be any composition that induces an immune response.
[0194] "Targeted knockout" is a widely used genetic engineering technique that involves the targeted destruction (e.g., removal or inactivation) of specific genes in an organism's genome.
[0195] The terms “sidecarrier,” “iron sidecarrier,” or “iron chelator” are used interchangeably herein and refer to compounds with a high affinity for iron, such as small compounds with a high affinity for iron. Sidecarriers of Gram-negative bacteria include, for example, enterobacterin and dihydroxybenzoylserine synthesized by Salmonella, Escherichia coli, Klebsiella, Shigella, and Serratia (but used by all Enterobacteriaceae); fluorescein synthesized by Pseudomonas aeruginosa; vibriin synthesized by Vibrio; acinetoferrin synthesized by Acinetobacter; Yersin and aerobicin synthesized by Yersinia; ornibactin synthesized by Burkholderia; salmonin synthesized by Salmonella; aerobicin synthesized by Escherichia coli, Shigella, Salmonella, and Yersinia; alkaloidin synthesized by Bouteris; and bisucarin synthesized by Vibrio. Siderophores include isohydroxamic acid, catechol, and mixed ligand siderophores.
[0196] As used in this article, the term "Salmonella" includes all Salmonella species, including Salmonella Enterica and Salmonella Bongo. The most well-known serotypes include typhoid, paratyphoid, enterotyphoid, typhus mollusc, and swine cholera.
[0197] Example The following examples describe some exemplary ways of preparing and carrying out certain compositions and methods described herein. These examples are for illustrative purposes only and are not intended to limit the scope of the compositions and methods described herein.
[0198] Examples 1-3 involve genetically modified Escherichia coli, while Example 4 involves genetically modified Salmonella.
[0199] Example 1: Attenuating E. coli by deleting chromosomal auxotroph genes and ion transport genes In this embodiment, a pathogenic APEC bacterial strain is modified to induce chromosome disruption in both the auxotrophic gene and the Pst operon. As an illustrative example, the auxotrophic gene is... glmS Gene.
[0200] glmS-pstSCA Mutations in operons Amplification Using the following primer set, the nucleic acid sequence with SEQ ID NO: 1 was amplified from Escherichia coli by PCR. glmS-pstSCA Operator fragments: CMD1347: CTGGCCGGCGCGCCCCGGTCACATGGGATGAGGAG (SEQ ID NO: 2) CMD1349: CAGACGTTAATTAAAAGCGATGTTGTCGTAGATGG (SEQ ID NO: 3).
[0201] connect The obtained fragments were digested with AscI and PacI and ligated into the AscI-PacI digested pMEG-375 plasmid (Dozois CM, Daigle F., Curtiss R. (2002). Identification of pathogen-specific and conserved genes expressed in vivo by an avian pathogen). Escherichia coli strain. Proc. Natl. Acad. Sci. USA In SEQ ID NO: 4, the allelic exchange plasmid pIJ355 (SEQ ID NO: 4) was generated. pMEG-375 (sacRB mobRP4 oriR6K. Cm R Ap R ) is a sucrose-sensitive (possessing the sacRB genetic determinant that confers sucrose sensitivity) reselective suicide plasmid that cannot replicate in standard E. coli strains. Figure 2 The spectrum of the allelic exchange plasmid pIJ355 is shown.
[0202] Transformation: The pIJ355 plasmid was then transformed into... Zygote Escherichia coli donor strain In order to allow pIJ355 plasmid to replicate and integrate into the genome via single crossover homologous recombination. glmS-pstSCA In the locus. E. coli The donor strain is an auxotroph for diaminopimelic acid (DAP). E. coli The donor strain is auxotrophic to DAP, which provides efficient post-conjugation anti-selection based on DAP deprivation to facilitate plasmid transfer.
[0203] choose Following conjugation transfer, pIJ355 integrates into the body via single-cross homologous recombination. glmS-pstSCA In the locus, growth was selected using kanamycin without DAP supplementation. The viable bacteria were then spread onto agar plates supplemented with sucrose, kanamycin, and NAG to select for double-crossing allelic exchange.
[0204] First, colonies were isolated based on kanamycin resistance, and because they exhibited a BCIP-degradation phenotype, blue colonies were produced when BCIP was added to the plates. Colonies were also screened by PCR using the following primer set for confirmation. glmS- pstSCA Disruption of a gene locus (i.e., deletion): CMD1345: AGCCCTAGGCCGCAGACTCAGAAAGAAGG (SEQ ID NO: 5) CMD1042: ATCGCGGTGATTGCATCAGAAAGC (SEQ ID NO: 6).
[0205] The results were further confirmed by comparing bacteria cultured on Luria-Bertani (LB) agar plates (e.g., LB: 10 g / L tryptone, 5 g / L yeast extract, 10 g / L sodium chloride), LB supplemented with N-acetylglucosamine (NAG), LB supplemented with BCIP, and LB supplemented with both NAG and BCIP. glmS-pstSCA Disruption of gene loci ( Figure 3 A to Figure 3 D). For example, having been damaged. glmS-pstSCA Bacteria from the locus do not grow on plates without NAG supplementation.
[0206] Example 2: Preparation of Escherichia coli rescue plasmid In this embodiment, the pAPEC-1 virulence plasmid is modified to (a) disrupt... iuc Operator, (b) destruction iro Operators and (c) introduce functionality therein glmS Genes generate DNA rescue molecules.
[0207] The table below lists the PCR primers used in this example.
[0208]
[0209] a) iuc Manipulator destruction Amplification Using pABN5 (McDougall S, Neilands JB) (SEQ ID NO: 7) as a template, the following primer set was used for inverse PCR amplification of the circular plasmid to remove plasmids containing pABN5. iucABCD Regions of the gene: CMD1328 CCACCGTTTTGAAGTTCTGAG (SEQ ID NO: 8) CMD1329 GGGAACAGCCATTGATTGTC (SEQ ID NO: 9) connect The linear PCR products were ligated together to generate plasmid pIJ339.
[0210] Subcloning to pBlueScript II Then, pIJ339 was digested with SalI and AvrII to produce a fragment containing the target gene (SEQ ID NO: 10). This fragment was then ligated into a pBlueScriptII plasmid (Agilent Technologies) digested with SalI and XbaI to generate plasmid pIJ345. Subsequently, pIJ345 plasmid was digested with BssHII to produce a fragment containing the target gene. iucA and iucD A fragment of a gene (SEQ ID NO: 11).
[0211] connect The result contains iucA and iucD A portion of the gene was ligated into the ascitic, reselective suicide vector pMEG-375 to generate plasmid pIJ346. Figure 4 (SEQ ID NO: 12).
[0212] Transformation Then pIJ346 was transformed into a recipient strain that required DAP ( In this context, it serves as a means to transfer pIJ346 to the APEC strain. The donor in the process.
[0213] transfer Then the pIJ346 plasmid was transferred to the APEC strain. After transfer, pIJ346, which could not replicate in APEC strains, was then integrated into the strain via single crossover homologous recombination. iucABCD Within gene clusters.
[0214] choose Selected colonies were grown and spread onto sucrose-containing agar plates to promote allelic exchange following double-cross recombination. This resulted in the selection of pAPEC-1 with mutations and those with disruptions. iucA '-' iucD Mutants of genes, which are transmitted through... iuc Targeted disruption of the operon eliminated the synthesis of aerobicin siderophores.
[0215] Double mutants were visually selected on chrome azure-S (CAS) agar plates because the yellow halo that is usually present around these colonies was reduced due to the loss of aerobicin synthesis.
[0216] The following primer set was also used to confirm the results by PCR (not shown). iuc Gene deletion: Aero1: GCTCTAGATTATGATCCTGCCCTCTG (SEQ ID NO: 13) Aero4:ATGCATGCTGAAGCTGAGTGTACC (SEQ ID NO: 14).
[0217] b) iro Operational damage and functionality glmS The introduction Amplification The following primer set was used to amplify Escherichia coli bacteria by PCR. glmU-glmS Operators to generate glmU-glmS Fragment (SEQ ID NO: 17): CMD1344:GCGAAGCTTCCGTCCTGAATAGCGTTCAC (SEQ ID NO: 15) CMD1310: GATAAGCTTAGCATTGTTTGTTGGCTACG (SEQ ID NO: 16).
[0218] connect Then digest with HindIII glmU-glmS The fragment and pBC-SK+ plasmid (Agilent Technologies) were combined, and the fragment was ligated into pBC-SK+ to generate plasmid pIJ352.
[0219] Mutation in the glmS operon (removal of glmU) The following primer set was used to amplify pIJ352 by reverse PCR to remove [the virus]. glmU Genes, making glmS In P glmu-glmS Under the control of the promoter: CMD1345: AGCCCTAGGCCGCAGACTCAGAAAGAAGG (SEQ ID NO: 5) CMD1346 TGCCCTAGGCTGCGGCAAGGATCACTAC (SEQ ID NO: 18) The resulting fragment (SEQ ID NO: 19) was digested with AvrII and linked and circularized to generate plasmid pIJ356.
[0220] Amplification of the mutant glmS gene Then, pIJ356 was used as a template to amplify using the following primer set. glmSGenes and their promoters: CMD1380 CGACGGTATTAATTAACTTCCGTCCTGAATAGCGTTC (SEQ ID NO: 20) CMD1381 GAATTCGATTTAATTAATAGCATTGTTTGTTGGCTACG (SEQ ID NO: 21).
[0221] Linkage of the mutated glmS gene The obtained fragment (SEQ ID NO: 22) was digested with PacI and cloned into plasmid pIJ20 (pYA3661 - Charles M. Dozois, France Daigle, Roy Curtiss,III) that had been digested with PvuI to generate plasmid pIJ372.
[0222] The mutant glmS gene was introduced into pMEG-375. pIJ372 was digested with SphI and the resulting iroB'-PglmS-'iroE fragment was ligated into the SphI-digested suicide vector pMEG-375 to generate the pIJ379 allelic exchange vector. Figure 5 (SEQ ID NO: 23).
[0223] Transformation Transform pIJ379 into a DAP-requiring conjugative Escherichia coli donor strain. In the middle, they are used as donors for transferring suicide vectors.
[0224] transfer Then, the pIJ379 plasmid was transferred into the modified APEC strain. This includes those with damage iucABCD The mutated pAPEC-1 plasmid was transferred. After transfer, plasmid pIJ379 integrated into the gene via single crossover homologous recombination. iroB- iroE within the cluster.
[0225] choose Selected colonies were grown and spread onto sucrose-containing agar plates to promote double cross-recombination, resulting in the iroB-iroE gene being... glmS Functional copy allelic substitutions of genes. This leads to selection with disrupted genes. iroBCDE Mutants in genes.
[0226] The resulting colonies also grew on sucrose-containing plates without NAG supplementation. Colonies were also visually identified by adding BCIP to the growth medium. The following primer set was used to confirm the cause of [the colony's formation] by PCR. iroBCDE Gene deletion and having iroB' - PglmS-'iroE Allelic crossing: CMD958:GAGAGAAGGCCCGAGCGTAAACGTCTGCTG (SEQ ID NO: 24) CMD1345: AGCCCTAGGCCGCAGACTCAGAAAGAAGG (SEQ ID NO: 5).
[0227] The resulting mutant pAPEC-1 plasmid ( It does not contain functional toxicity genes. iuc and iro And includes functionality glmS Gene.
[0228] Transferred to donor strains for future vaccine development The mutant pAPEC 1 plasmid vector was transferred to the laboratory strain of Escherichia coli S17 lamba-pir via conjugation mating to serve as a donor strain for all further transfers to strains intended for use as potential vaccines.
[0229] Example 3: Generation of gene-modified APEC carrying rescue plasmid Through missing glmS-pstSCA The genetically modified APEC strain can be used as a recipient for plasmid vector conjugation transfer based on the mutant pAPEC-1 plasmid of Example 2.
[0230] The resulting recombinant bacteria were then grown on plates without NAG supplementation, which resulted in the selective loss of the native pAPEC-1 virulence plasmid, since the plasmid vector and the native pAPEC-1 virulence plasmid have the same replication system, but only the plasmid vector contains the required auxotrophic gene.
[0231] The resulting recombinant bacteria lost two siderophore coding systems and lacked chromosome coding. pst It has reduced toxicity due to its genes.
[0232] The plasmid vector is selectively retained in recombinant bacteria in vivo (because this is an environment that is usually lacking in NAG) and on plates without supplemented NAG.
[0233] Genetically modified APEC strain—serotype O7 In this embodiment, by missing glmS-pstSCA A plasmid vector based on the mutant pAPEC-1 plasmid from Example 2 was introduced to modify the genes of the APEC O7 strain.
[0234] The mutant pAPEC-1 plasmid vector was transferred into the APEC O7 strain. Using S17 lamba- from Example 2 pirDonor strains, via conjugation transfer, will transfer plasmids based on the mutant pAPEC-1 (Δ) iuc Δ iro :: P glmS The plasmid vector was transferred to... glmS-pstSCA APEC O7 strains with gene disruption (deletion) (Δ) glmS - pstSCA ).
[0235] choose Colonies receiving the transfer were selected by growing bacteria on agar plates supplemented with kanamycin (for anti-selection of donor strains) but without NAG supplementation (to ensure the acquisition of the mutant pAPEC-1 plasmid vector). Therefore, only recipients that received a copy of the mutant pAPEC-1 plasmid vector could grow on this medium. PCR targeting the deletion was also performed using the following primer set. pstSCA The system screened the obtained colonies: CMD1345: AGCCCTAGGCCGCAGACTCAGAAAGAAGG (SEQ ID NO: 5) CMD1042 ATCGCGGTGATTGCATCAGAAAGC (SEQ ID NO: 6) Colonies were also identified on LB agar plates, LB + NAG, LB + BCIP, and LB + NAG + BCIP. Figure 6 A, Figure 6 B Figure 6 C Figure 6 D). Finally, colonies were screened by PCR to confirm the presence of the mutant pAPEC-1 plasmid vector and the absence of the required aerobicin and salmonellin siderophores, respectively. iuc and iro Genes (not shown).
[0236] The final step in generating APEC mutant vaccine strain candidates is to remove sites flanking FRT-containing sites used for generation. glmS-pstSCA The kanamycin resistance cassette was achieved through a deletion mutation. This was accomplished via FLP-mediated recombinant excision of the kanamycin resistance cassette provided by plasmid pCP20 (Cherepanov PP, Wackernagel W.). The pCP20 plasmid was then lost through heat shock following incubation at 42°C.
[0237] The resulting recombinant bacteria were deposited with the International Depository of Canada (IDAC) on December 20, 2023, under accession number 201223-01.
[0238] Preparation of O7 vaccine composition Colonies of the genetically modified O7 APEC strain, deposited under accession number 201223-01, were inoculated into brain-heart infusion (BHI) liquid medium to obtain a culture broth. On the day of inoculation, the culture broth was centrifuged at 4000 rpm for 10 min at room temperature to obtain a pellet. The pellet was resuspended in phosphate-buffered saline (PBS) to a final concentration of 1.3 x 10⁻⁶. 10 CFU / mL (based on optical density and CFU count) was used to obtain the vaccine composition.
[0239] Efficacy evaluation of O7 E. coli vaccine candidates in homologous protection Based on whether they received the vaccine composition (Treatment 1) or the same volume of PBS (Treatment 2), 32 specific pathogen-free (SPF) White Leghorn chickens (both sexes) were separated into different isolation rooms. The treatment was administered orally on the second / third day after hatching of all birds (the animals were turned over to allow the vaccine strain to reach the nostrils and trachea). Chickens that received only PBS were kept in separate isolation rooms to prevent cross-contamination.
[0240] Chickens in isolation room 1 were orally vaccinated on day 0 with 100 µL (1.3 x 10⁻⁶) of vaccine. 9 The candidate vaccine strain O7 (CFU) from Example 3. The unvaccinated group (control) received 100 µL of PBS orally.
[0241] Nineteen days after vaccination, 100 µL (containing 5.00 × 10⁻⁶ mmol / L) was injected directly into the left chest balloon. 7 To challenge chickens in the isolation room with the virulence strain O7.
[0242] a) Health monitoring and observation of clinical signs Monitor chickens in all groups for any clinical signs (behavior, posture, eye opening, and signs of respiratory distress) and mortality on specific dates until day 21. After vaccination, chickens were examined on days 0 and 1, and then every 3 days until day 18. Following challenge, chickens were examined on days 19 and 20 (3 times daily).
[0243] b) Autopsy Two days after challenge, all chickens in the study underwent necropsy to examine for visible lesions in the air sacs, heart, and liver. Macroscopic fibrinous lesions on organs were examined according to Table 1 (Description of Chicken Lesions).
[0244] c) Detection of challenge strains Bacterial levels in chicken blood were determined by bacterial counts from agar plates inoculated with blood samples collected at 6, 24, and 48 h post-challenge. Following necropsy, the right lung, spleen, and liver were harvested and homogenized using an Ultra-Turrax homogenizer. The supernatant was serially diluted in sterile PBS, and each dilution was plated onto MacConkey agar plates. The plates were incubated at 37°C ± 2°C for 16 to 18 h.
[0245] d) Statistical analysis Using Graph Pad Prism TM 9 software (GraphPad) TM (Software, San Diego, CA, USA) The Mann-Whitney test was used to compare the statistical differences in lesion scores and bacterial counts recovered from blood and tissues between the vaccinated chicken group and the control group. A p-value ≤ 0.05 was considered significant.
[0246]
[0247] Studies on the effectiveness of vaccines using genetically modified strains have shown that the O7 strain reduced mortality in chickens infected with virulent strains (see Table 2).
[0248] Survival rate Symptoms appeared 6 hours after challenge, and mortality was predominant in the placebo group 48 hours after challenge. In total, 31% (5 / 16) of the unvaccinated birds died 48 hours after challenge with the virulent O7 strain. In contrast, no deaths were observed in the vaccinated group, with all 16 birds surviving 48 hours after infection.
[0249]
[0250] The effectiveness of vaccination Escherichia coli infection At 6 h, the median level of bacterial colonization in the blood of unvaccinated chickens was 1.32 x 10⁻⁶. 3 CFU / mL, while the level in vaccinated chickens was 5.25 x 10⁻⁶. 2 CFU / mL ( Figure 8A , Figure 8B , Figure 8C 24 hours after challenge, the bacterial titer in the blood of unvaccinated birds was 1.92 x 10⁻⁶. 3 CFU / mL, compared to 45 CFU / mL in vaccinated birds. At 48 h, the titer in the control group decreased to 3.43 x 10⁻⁶. 2The titer was CFU / mL, while it was almost undetectable in vaccinated birds (5 CFU / mL). Therefore, the vaccine resulted in a reduction in the spread of E. coli into the bloodstream at all time points.
[0251] Compared with the placebo group, the bacterial counts in the lungs, spleen, and liver of vaccinated chickens were significantly lower. Figure 9A , Figure 9B , Figure 9C ).
[0252] lesion score Gross lesions associated with E. coli infection observed in the left air sac (vaccination site and infection site) of infected chickens appeared to correlate with bacterial levels detected in tissues across all animals.
[0253] Compared with placebo, vaccination significantly reduced lesion levels (p=0.0110). Figure 10 ).
[0254] Example 4: Attenuated Salmonella enterica typhus serotype In this embodiment, a genetically modified enteric Salmonella typhimurium serotype was generated using a method similar to that described in Example 1.
[0255] The following primer set was used to screen colonies by polymerase chain reaction (PCR) to identify enteric Salmonella typhimurium serotype. glmS-pstSCA Disruption of a gene locus (i.e., deletion): CDM3082: CGTTATTGGCGATGACTGCG (SEQ ID NO: 25) CMD3083: GCCCGATAAATGCCGTTACC (SEQ ID NO: 26) Figure 16 The results show that using primers CMD3082 / 3083 in SL1344 Δ glmS Δp stSCA A 2297 bp band was produced in strain QT6282, confirming the presence of a band in chromosome SL1344. glmS and pstSCA Successful deletion was performed. The ladder used was GeneRuler DNA Ladder Mix SM0331. If the deletion was positive, a band would be visible at 2297 bp. If there was no deletion, a band would be visible at 11538 bp.
[0256] via GenScript glmU-glmS promoter along with the entire length glmS Genes and encoding gentamicin resistance aac1The gene is synthesized into a single DNA fragment. This DNA fragment is then cloned into a gene containing the restriction sites PacI and PmeI. sacB The pIJ658 plasmid was generated by inserting the allelic exchange vector pMEG-375.
[0257] Transform plasmid pIJ658 into In DAP strains, they serve as donors for transferring suicide vectors, thereby enabling functional... glmS Gene introduction is lacking glmS-pstSCA The pSLT_SL1344 virulence plasmid in *Salmonella enterica* serotype SL1344-derived strains promotes... SL1344_P1_0073 Allelic substitution of genes.
[0258] After transfer, plasmid pIJ658 was integrated into the target cell via single crossover homologous recombination. SL1344_P1_0073 Within the gene. Selected colonies are then grown and spread on sucrose-containing plates to promote double cross-recombination events, leading to... SL1344_P1_0073 Allelic substitution glmS Functional copies of the gene. Therefore, the resulting colonies were able to grow on sucrose-containing plates without N-acetylglucosamine supplementation. The cause was also confirmed by PCR screening. SL1344_P1_0073 Gene deletion and having PglmS-aac1 Allelic exchange of alleles.
[0259] The purpose of this PCR was to confirm the successful insertion of the glmS gene in strain QT6282 (mixed PCR examination of glmSCMD3294 / 3295) and whether glmS was inserted into the pSLT plasmid (mixed PCR of CMD3297 / 3298).
[0260] Clones in pSLT were screened by PCR using the following primers. glmS : CDM3294:GCTGGGATTTGGGCTCTC (SEQ ID NO: 27) CMD3295:GATGTGCATGTTGTCGTTGC (SEQ ID NO: 28) if glmS+ The band is at 592 bp. If glmS- No stripes.
[0261] The insertion region (SL1344_RS24025) was screened by PCR using the following primers: CMD3297:ATCCGGACCGTGCCTTATAC (SEQ ID NO: 29) CMD3298:ACACGCTTATCCAACGACACG (SEQ ID NO: 30) like Figure 14A and Figure 14B As shown, in strain SL1344 which lacks... glmS After gene modification, the bacteria were unable to grow in media lacking N-acetylglucosamine (NAG). In fact, *Salmonella typhimurium* SL1344 Δ glmS Δ pstSCA It did not grow on M9 agar plates supplemented with BCIP (50 μg / ml), but grew as blue colonies on M9 agar plates supplemented with NAG (250 μg / ml) and BCIP (50 μg / ml). In contrast, the wild-type SL1344 strain grew well on M9 agar plates supplemented with BCIP (50 μg / ml). Figure 15 As shown in the diagrams, these growth plots demonstrate that the methods for rescuing DNA molecules and auxotrophic genes to mitigate chromosomal damage function well in Salmonella, similar to the case in E. coli.
[0262] Confirmation of attenuated enteric Salmonella in typhus cases Colonies of genetically modified Salmonella typhimurium (QT6282) and wild-type parental Salmonella typhimurium QT1573 (SL1344 WT) were inoculated into LB liquid medium to obtain a culture broth, which was then frozen in 50% glycerol at -80°C. On day -1 (before inoculation), mice were treated with streptomycin at 20 mg in 100 µL sterile water by oral gavage to disrupt the microbiota and promote the ability of SL1344 to infect the intestines of C57BL / 6 mice.
[0263] On the day of challenge, the frozen tubes of the strains were thawed. Two doses (low and high) were prepared by 1:10 serial dilutions of each strain. The serial dilutions were plated on MacConkey agar supplemented with 250 µg / mL NAG, 50 µg / mL BCIP, and 50 µg / mL streptomycin. The plates were incubated at 37°C for 16–18 hours to confirm bacterial counts. Twenty-three healthy female C57BL / 6 mice were ordered. The mice were randomly placed in individual cages and assigned unique identifiers (1–23).
[0264] Mice were divided into groups and challenged orally by gavage with either the wild-type strain (QT1573) or the mutant strain (QT6282). Two doses were administered (low and high): a low-dose group for assessing mortality, and a high-dose group for assessing organ colonization. A control group of three mice was used as the unchallenged group.
[0265] a) Health monitoring and observation of clinical signs Monitor mice in all groups for any clinical signs (behavior, posture, eye opening, and signs of respiratory distress) and mortality on specific dates up to day 6 post-challenge.
[0266] b) Autopsy Six days after challenge, all mice in the study underwent necropsy. Spleen, cecum, and liver were harvested and homogenized for bacterial counting.
[0267] c) Statistical Analysis Using Graph Pad Prism TM 9 software (GraphPad) TM (Software, San Diego, CA, USA) compared mice challenged with QT1573 (SL1344 WT) and mice challenged with QT6282 (SL1344 Δ) using the Mann-Whitney test. glm S- Δ pstSCA - pSLT- glmS +) Statistical differences in bacterial counts recovered from tissues between challenged mice. A p-value ≤ 0.05 was considered significant.
[0268] Toxicity assessment QT6282 strain (Salmonella enterica SL1344, typhoid fever) ΔglmS- ΔpstSCA- pSLT:: glmS + The virulence evaluation showed a significant reduction in virulence compared to the wild-type (WT) strain.
[0269] The genetically modified strain did not cause death in mice, in contrast to the WT strain. Furthermore, the colonization levels of QT6282 in the liver and spleen were significantly lower than those of the WT strain, further confirming its genetic modification profile. Figures 13A to 13C As shown.
[0270] Survival analysis (low-dose infection) C57BL / 6 mice challenged with a low dose of the WT strain began to die 5 days post-challenge. In total, 3 out of 5 mice (60% mortality rate) died within 6 days. Conversely, no deaths were observed in mice challenged with QT6282, highlighting the safety of the mutant strain. Figure 12 As shown.
[0271] Organ colonization (high-dose infection) Compared to QT6282, the median bacterial colonization level in organs of the WT strain was significantly higher. Notably, the liver and spleen colonization levels of QT6282 were significantly lower than those of QT1573, confirming its gene-modification ability for organ colonization, such as... Figure 13A, Figure 13B , Figure 13C As shown.
[0272] Surprisingly, despite having only pst The disruption of the gene sequence—that is, without further disruption of one or more virulence factors—appears to be genetically modified, as shown in the mouse model used.
[0273] These data indicate that virulent Salmonella can be genetically modified by deleting only the phosphate transport system gene, resulting in attenuated Salmonella.
[0274] Given the teachings of this specification, other examples of implementation will become clear to the reader and will therefore not be described further here.
[0275] Note that headings or subheadings may be used throughout this disclosure for the convenience of the reader, but these should in no way limit the scope of the invention. Furthermore, certain theories may be proposed and disclosed herein; however, whether correct or not, they should in no way limit the scope of the invention as long as the invention is practiced according to this disclosure without regard to any particular theory or course of action.
[0276] All references cited throughout this specification are incorporated herein by reference in their entirety for all purposes.
[0277] Throughout this specification, references to "some embodiments" and the like mean that a particular element (e.g., feature, structure, and / or characteristic) described in connection with the invention is included in at least one embodiment described herein and may or may not be present in other embodiments. Furthermore, it should be understood that the described inventive features can be combined in any suitable manner in the various embodiments.
[0278] Those skilled in the art will understand that throughout this specification, the term "a" as used before a term encompasses one or more embodiments referred to by that term. Those skilled in the art will also understand that throughout this specification, the terms "comprising," "including," "containing," or "characterized in" are synonymous, inclusive or open-ended, and do not exclude additional, unlisted elements or method steps.
[0279] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In case of conflict, this document (including definitions) shall prevail.
[0280] As used in this disclosure, the terms “approximately,” “about,” or “probably” should generally be intended to mean a range of error commonly accepted in the art. Therefore, the numerical quantities given herein generally include such ranges of error so that the terms “approximately,” “about,” or “probably” can be inferred even if not explicitly stated.
[0281] Although various embodiments of this disclosure have been described and illustrated, those skilled in the art will understand, in light of this description, that many modifications and variations can be made. The scope of the invention is defined more specifically in the appended claims.
Claims
1. A composition comprising genetically modified bacteria, wherein, The genetically modified bacteria include: a) Chromosomal disruption in auxotrophic genes and in one or more genes involved in phosphate regulation, and b) A DNA rescue molecule containing a functional copy of the aforementioned auxotrophic gene. The genetically modified bacteria were obtained from pathogenic bacteria containing virulence plasmids.
2. The composition according to claim 1, wherein, The genetically modified bacteria are Gram-negative bacteria.
3. The composition according to claim 1, wherein, The genetically modified bacteria belong to the Enterobacteriaceae family.
4. The composition according to claim 1, wherein, The genetically modified bacteria is Escherichia coli (Escherichia coli) Escherichia coli () E. coli ), Shigella ( Shigella Edwardsiella pneumoniae ( Edwardsiella ),salmonella( Salmonella ), Citrobacter ( Citrobacter Klebsiella pneumoniae ( Klebsiella ), Enterobacteriaceae ( Enterobacter Serratia marcescens ( ) Serratia ), Proteus ( Proteus Morganella morganii ( Morganella Providencia ( Providencia ) and Yersinia ( Yersinia At least one of the following, preferably Escherichia coli (E. coli) Escherichia coli ) ( E. coli ) or Salmonella ( Salmonella ).
5. The composition according to any one of claims 1 to 4, wherein, The chromosome disruption includes the insertion, deletion, modification, or replacement of DNA.
6. The composition according to claim 5, wherein, The chromosome disruption includes the deletion of at least a portion of the auxotrophic gene.
7. The composition according to any one of claims 1 to 6, wherein, The auxotrophic genes are required for the synthesis of peptidoglycan in bacterial cell walls.
8. The composition according to claim 7, wherein, The auxotrophic gene is glmS Gene.
9. The composition according to any one of claims 1 to 8, wherein, The one or more genes involved in phosphate regulation include phosphate transport system operons ( pst One or more genes of an operon.
10. The composition according to claim 9, wherein, The pst One or more genes of the operon are selected from pstS , pstC , pstA ,and pstB .
11. The composition according to claim 9 or 10, wherein, The chromosome damage includes the following pst The deletion of at least a portion of one or more genes in the operon.
12. The composition according to any one of claims 9 to 11, wherein, glmS Genes and the pst One or more genes of an operon are consecutive chromosomal genes.
13. The composition according to any one of claims 1 to 11, wherein, The DNA rescue molecule is a plasmid vector or a DNA box.
14. The composition according to claim 13, wherein, The plasmid vector contains a replication origin that is incompatible with the replication origin of the bacterial virulence plasmid.
15. The composition according to claim 14, wherein, The bacterial virulence plasmid includes one or more genes derived from a siderophore system.
16. The composition according to claim 15, wherein, The ferrocarrier system includes from iuc Operators and / or iro One or more genes of an operon.
17. The composition according to any one of claims 14 to 16, wherein, The plasmid vector is a copy of a bacterial virulence plasmid that has been modified by inserting a functional copy of the auxotroph gene at a DNA location corresponding to one or more genes of the siderophore system in the bacterial virulence plasmid.
18. The composition according to claim 17, wherein, The plasmid vector further includes a functional gene encoding a siderophore outer membrane receptor, preferably a functional gene encoding the siderophore outer membrane receptor IutA required for aerobicin uptake and the siderophore receptor IroN required for salmonellin uptake.
19. A vaccine for the prevention of bacterial infectious diseases, comprising a composition according to any one of claims 1 to 18 and a pharmaceutically or veterinarily acceptable excipient, diluent, or carrier.
20. The vaccine of claim 19, which is suitable for oral, ocular, transdermal, transmucosal, intravenous, subcutaneous, intramuscular, intradermal, intraperitoneal, intracystic, intraspinal, intrasternal, intrapulmonary, intranasal, vaginal, rectal, intraocular, intrathecal, buccal, respiratory, local, ingested, or locally delivered administration.
21. The vaccine according to claim 19 or 20, which is suitable for administration to avian species.
22. The vaccine according to claim 21, wherein, The poultry species are at least one of chicken, duck, turkey, goose, dwarf chicken, quail, pheasant, and pigeon.
23. A method for inducing an immune response in a host, the method comprising administering to the host an effective amount of the composition according to any one of claims 1 to 18.
24. The method according to claim 23, wherein, The composition may be administered orally, ocularly, transdermally, transmucosally, intravenously, subcutaneously, intramuscularly, intradermally, intraperitoneally, intracystically, intraspinally, intrasternally, intrapulmonaryly, intranasally, vaginally, rectally, intraocularly, intrathecally, buccally, inhaled, locally, by ingestion, or by local delivery.
25. The method according to claim 23 or 24, wherein, The host is a bird species.
26. The method of claim 25, wherein, The poultry species are at least one of chicken, duck, turkey, goose, dwarf chicken, quail, pheasant, and pigeon.
27. A method for preparing a live attenuated vaccine from a virulent pathogen containing a virulence plasmid, comprising: a) Causes chromosome damage in the said pathogenic bacteria, the chromosome damage being located in auxotrophic genes and one or more genes involved in phosphate regulation, and b) Introduce a DNA rescue molecule containing a functional copy of the auxotrophic gene into the bacteria.
28. The method according to claim 27, wherein, The pathogenic bacteria are Gram-negative bacteria.
29. The method according to claim 27, wherein, The toxic pathogens belong to the Enterobacteriaceae family.
30. The method of claim 27, wherein, The toxic pathogen is Escherichia coli (Escherichia coli) Escherichia coli () E. coli Shigella ( Shigella Edwardsiella pneumoniae ( Edwardsiella) ,salmonella( Salmonella ), Citrobacter ( Citrobacter Klebsiella pneumoniae ( Klebsiella ), Enterobacteriaceae ( Enterobacter Serratia marcescens ( ) Serratia ), Proteus ( Proteus Morganella morganii ( Morganella Providencia ( Providencia ) and Yersinia ( Yersinia At least one of the following, preferably Escherichia coli (E. coli) Escherichia coli ) ( E. coli ) or Salmonella ( Salmonella ).
31. The method according to any one of claims 27 to 30, wherein, The chromosome disruption includes the insertion, deletion, modification, or replacement of DNA.
32. The method according to claim 31, wherein, The chromosome disruption includes the deletion of at least a portion of the auxotrophic gene.
33. The method according to any one of claims 27 to 32, wherein, The auxotrophic genes are required for the synthesis of peptidoglycan in bacterial cell walls.
34. The method according to claim 33, wherein, The auxotrophic gene is glmS Gene.
35. The method according to any one of claims 27 to 34, wherein, The one or more genes involved in phosphate regulation include phosphate transport system operons ( pst One or more genes of an operon.
36. The method according to claim 35, wherein, The pst One or more genes of the operon are selected from pstS , pstC , pstA ,and pstB .
37. The method according to claim 35 or 36, wherein, The chromosome damage includes the following pst The deletion of at least a portion of one or more genes in the operon.
38. The method according to any one of claims 35 to 37, wherein, glmS Genes and the pst One or more genes of an operon are consecutive chromosomal genes.
39. The method according to any one of claims 27 to 38, wherein, The DNA rescue molecule is a plasmid vector or a DNA box.
40. The method according to claim 39, wherein, The plasmid vector contains a replication origin, which is incompatible with the replication origin of the virulence plasmid.
41. The method according to claim 40, wherein, The virulence plasmid includes one or more genes from a siderophore system.
42. The method according to claim 41, wherein, The ferrocarrier system includes from iuc Operators and / or iro One or more genes of an operon.
43. The method according to any one of claims 40 to 42, wherein, The plasmid vector is a copy of a virulence plasmid modified by inserting a functional copy of the auxotroph gene at a DNA location corresponding to one or more genes of the siderophore system in the virulence plasmid.
44. The method according to claim 43, wherein, The plasmid vector further includes a functional gene encoding a siderophore outer membrane receptor, preferably a functional gene encoding the siderophore outer membrane receptor IutA required for aerobicin uptake and the siderophore receptor IroN required for salmonellin uptake.
45. A method for delivering a therapeutic payload in cancer treatment, comprising administering to a host suffering from cancer the composition according to any one of claims 1 to 18, wherein, The DNA rescue molecule further includes a recombinant gene encoding the therapeutic payload.
